PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
22539851-8	2012	In Gnal+/- mice, the lesion-induced L-DOPA stimulation of cAMP/PKA-mediated phosphorylation of GluA1 Ser845 and DARPP-32 (32 kDa DA- and cAMP-regulated phosphoprotein) Thr34 was dramatically reduced, whereas ERK activation was preserved.	Levodopa	36-42	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-120
22539851-8	2012	In Gnal+/- mice, the lesion-induced L-DOPA stimulation of cAMP/PKA-mediated phosphorylation of GluA1 Ser845 and DARPP-32 (32 kDa DA- and cAMP-regulated phosphoprotein) Thr34 was dramatically reduced, whereas ERK activation was preserved.	Cyclic AMP	58-62	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-120
22424902-3	2012	Transplantation of these human forebrain GABA neurons and their progenitors, but not spinal GABA cells, into the striatum of quinolinic acid-lesioned mice results in generation of large populations of DARPP32(+) GABA neurons, which project to the substantia nigra as well as receiving glutamatergic and dopaminergic inputs, corresponding to correction of motor deficits.	gamma-Aminobutyric Acid	41-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	201-208
22424902-3	2012	Transplantation of these human forebrain GABA neurons and their progenitors, but not spinal GABA cells, into the striatum of quinolinic acid-lesioned mice results in generation of large populations of DARPP32(+) GABA neurons, which project to the substantia nigra as well as receiving glutamatergic and dopaminergic inputs, corresponding to correction of motor deficits.	Quinolinic Acid	125-140	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	201-208
21833500-6	2012	RESULTS: Inhibition of PDE4 by rolipram induced activation of cAMP/PKA signaling in cortical slices and in vivo, leading to the phosphorylation of DARPP-32 and other postsynaptic and presynaptic PKA-substrates.	Rolipram	31-39	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
22475209-5	2012	RESULTS: KI mice fed a curcumin-containing diet since conception showed decreased huntingtin aggregates and increased striatal DARPP-32 and D1 receptor mRNAs, as well as an amelioration of rearing deficits.	Curcumin	23-31	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	127-135
21833500-6	2012	RESULTS: Inhibition of PDE4 by rolipram induced activation of cAMP/PKA signaling in cortical slices and in vivo, leading to the phosphorylation of DARPP-32 and other postsynaptic and presynaptic PKA-substrates.	Cyclic AMP	62-66	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
21833500-7	2012	Rolipram also enhanced DARPP-32 phosphorylation invoked by D1 receptor activation.	Rolipram	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	23-31
21741919-14	2011	Knockdown of DARPP-32 in gastric cancer cells reduced the mean size of tumors in mice and increased their response to gefitinib.	Gefitinib	118-127	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	13-21
22419037-3	2012	We find that the basally-induced decrease in this phosphoprotein is the result of recruitment of the striatal dopamine D2 pathway, as evidenced by enhanced levels of D2 receptor (D2R) mRNA expression and D2R function as examined using the D2R antagonist, eticlopride, as well as alterations in the phosphorylation status of several downstream molecular targets of D2R"s, including CREB, DARPP-32, Akt and GSK3beta.	Dopamine	110-118	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	387-395
22250817-7	2012	Biochemical studies revealed a reduction in the levels of dopamine and cAMP-regulated phosphoprotein (DARPP-32) in the striatum of RCS KO mice.	Cyclic AMP	71-75	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	102-110
20977939-5	2011	Moreover, ampakine treatments prevented the decrease in total striatal area, blocked the loss of striatal DARPP-32 immunoreactivity and reduced by 36% the size of intra-nuclear huntingtin aggregates in R6/2 striatum.	ampakine	10-18	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
21814187-0	2011	Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32.	Haloperidol	0-11	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	120-128
21848865-4	2011	CPF potentiated protein kinase A (PKA)-dependent phosphorylation of the striatal protein dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) and the glutamate receptor 1 (GluR1) subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in mouse brain slices.	Dopamine	89-97	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	149-157
21848865-4	2011	CPF potentiated protein kinase A (PKA)-dependent phosphorylation of the striatal protein dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) and the glutamate receptor 1 (GluR1) subunit of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in mouse brain slices.	Cyclic AMP	103-107	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	149-157
21672554-8	2011	Morphological identification of co-cultured MSNs expressing a soluble fluorescent protein can be confirmed by immunochemical detection of DARPP-32 (Dopamine and cyclic AMP regulated phosphoprotein of 32kDa).	Dopamine	148-156	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	138-146
21672554-8	2011	Morphological identification of co-cultured MSNs expressing a soluble fluorescent protein can be confirmed by immunochemical detection of DARPP-32 (Dopamine and cyclic AMP regulated phosphoprotein of 32kDa).	Cyclic AMP	161-171	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	138-146
21746918-3	2011	Genome-wide microarrays in sodium-deficient mice or after ACTH infusion showed up-regulation of hypothalamic genes, including dopamine- and cAMP-regulated neuronal phosphoprotein 32 kDa (DARPP-32), dopamine receptors-1 and -2, alpha-2C- adrenoceptor, and striatally enriched protein tyrosine phosphatase (STEP).	Sodium	27-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	126-185
21746918-3	2011	Genome-wide microarrays in sodium-deficient mice or after ACTH infusion showed up-regulation of hypothalamic genes, including dopamine- and cAMP-regulated neuronal phosphoprotein 32 kDa (DARPP-32), dopamine receptors-1 and -2, alpha-2C- adrenoceptor, and striatally enriched protein tyrosine phosphatase (STEP).	Sodium	27-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	187-195
21746918-4	2011	Both DARPP-32 and neural plasticity regulator activity-regulated cytoskeleton associated protein (ARC) were up-regulated in lateral hypothalamic orexinergic neurons by sodium deficiency.	Sodium	168-174	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	5-13
21462262-10	2011	Immunohistochemistry revealed significant attenuation of 3-nitropropionic acid-induced loss of tyrosine hydroxylase and DARPP-32 positive neurons in substantia nigra pars compacta and striatum, respectively, in both erythropoietin-treated groups without significant group difference in the substantia nigra.	3-nitropropionic acid	57-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	120-128
20682746-4	2010	Using these mice, we found that the loss of DARPP-32 in striatonigral neurons decreased basal and cocaine-induced locomotion and abolished dyskinetic behaviors in response to the Parkinson"s disease drug L-DOPA.	Cocaine	98-105	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	44-52
21912697-7	2011	Our study revealed significant loss of dopamine and cAMP regulated phosphoprotein of 32 kDa (DARPP-32) and comparable changes in SST, N-methyl-D-aspartic acid receptors subtypes, calbindin and brain nitric oxide synthase expression as well as in key signaling proteins including calpain, phospho-extracellular-signal-regulated kinases1/2, synapsin-IIa, protein kinase C-alpha and calcineurin in SSTR1/5(-/-) and R6/2 mice.	Cyclic AMP	52-56	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	93-101
20888397-6	2010	In addition, we found increased striatal DARPP-32-Thr-75 phosphorylation in trained mice.	Threonine	50-53	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	41-49
21103339-6	2010	Of these genes, one functional cluster was identified, and this cluster (Darpp-32, Drd1a, and Rgs9) is an established modulator of dopamine signaling.	Dopamine	131-139	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	73-81
20720111-0	2010	Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine.	Amphetamine	124-135	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	69-76
20720111-9	2010	Such biochemical alteration selectively affected dopamine D(1)Rs since haloperidol, by blocking the tonic inhibition of D(2)R, unmasked a normal activation of striatal adenosine A(2A) receptor-mediated cAMP/PKA/DARPP32 cascade in mutants.	Haloperidol	71-82	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	211-218
20720111-11	2010	Overall, our results suggest that the paradoxical motor calming effect induced by these drugs in DAT-CI mutants depends on selective aberrant phasic activation of D(1)R/cAMP/PKA/DARPP32 signaling in response to increased striatal extracellular dopamine levels.	Cyclic AMP	169-173	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	178-185
20720111-11	2010	Overall, our results suggest that the paradoxical motor calming effect induced by these drugs in DAT-CI mutants depends on selective aberrant phasic activation of D(1)R/cAMP/PKA/DARPP32 signaling in response to increased striatal extracellular dopamine levels.	Dopamine	244-252	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	178-185
20682746-4	2010	Using these mice, we found that the loss of DARPP-32 in striatonigral neurons decreased basal and cocaine-induced locomotion and abolished dyskinetic behaviors in response to the Parkinson"s disease drug L-DOPA.	Levodopa	204-210	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	44-52
20682746-5	2010	Conversely, the loss of DARPP-32 in striatopallidal neurons produced a robust increase in locomotor activity and a strongly reduced cataleptic response to the antipsychotic drug haloperidol.	Haloperidol	178-189	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	24-32
20456289-0	2010	Ethanol-induced activation of AKT and DARPP-32 in the mouse striatum mediated by opioid receptors.	Ethanol	0-7	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	38-46
20456289-2	2010	Here we report that an acute ethanol challenge induces a robust phosphorylation of two key signal transduction kinases, AKT and DARPP-32, in the striatum of mice.	Ethanol	29-36	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	128-136
20423708-9	2010	DARPP-32 phosphorylation in striatum was selectively increased at the Cdk5 kinase substrate, Threonine75 (T75).	threonine75	93-104	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
19852993-2	2010	We determined the phosphorylation state of cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34 and of Extracellular Signal-regulated Protein Kinases 1/2 (ERK1/2), under basal conditions and after in vivo stimulation of A(2A) receptors by administration of the agonist CGS21680.	Cyclic AMP	43-47	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	84-92
20236221-4	2010	In this study, we investigated the role of adrenoceptors in the regulation of dopamine/dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) signaling by analyzing DARPP-32 phosphorylation at Thr34 [protein kinase A (PKA)-site] in mouse neostriatal slices.	Dopamine	78-86	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
20236221-4	2010	In this study, we investigated the role of adrenoceptors in the regulation of dopamine/dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) signaling by analyzing DARPP-32 phosphorylation at Thr34 [protein kinase A (PKA)-site] in mouse neostriatal slices.	Cyclic AMP	101-105	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
20236221-4	2010	In this study, we investigated the role of adrenoceptors in the regulation of dopamine/dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) signaling by analyzing DARPP-32 phosphorylation at Thr34 [protein kinase A (PKA)-site] in mouse neostriatal slices.	Cyclic AMP	101-105	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	180-188
19852993-6	2010	These results indicate that under chronic dopamine deficiency (a) the A(2A)/cAMP/PKA/DARPP-32 cascade is overactive due to the elevated endogenous phospho-DARPP-32 levels and (b) the A(2A) receptor modulatory effect on ERK1/2 signaling is dysregulated exerting opposing action compared to that observed in normal animals (Quiroz et al., 2006), i.e. in "weaver" animals A(2A) receptor blockade increases the activity of ERK1/2 cascade.	Cyclic AMP	76-80	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	85-93
19852993-6	2010	These results indicate that under chronic dopamine deficiency (a) the A(2A)/cAMP/PKA/DARPP-32 cascade is overactive due to the elevated endogenous phospho-DARPP-32 levels and (b) the A(2A) receptor modulatory effect on ERK1/2 signaling is dysregulated exerting opposing action compared to that observed in normal animals (Quiroz et al., 2006), i.e. in "weaver" animals A(2A) receptor blockade increases the activity of ERK1/2 cascade.	Cyclic AMP	76-80	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	155-163
19759531-9	2010	Sensitization to morphine injection was prevented in knockin mutant mice bearing a Thr-34-Ala mutation of DARPP-32, which suppresses its ability to inhibit protein phosphatase-1 (PP1), but not mutation of Thr-75 or Ser-130.	Morphine	17-25	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
19759531-9	2010	Sensitization to morphine injection was prevented in knockin mutant mice bearing a Thr-34-Ala mutation of DARPP-32, which suppresses its ability to inhibit protein phosphatase-1 (PP1), but not mutation of Thr-75 or Ser-130.	Threonine	83-86	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
19759531-9	2010	Sensitization to morphine injection was prevented in knockin mutant mice bearing a Thr-34-Ala mutation of DARPP-32, which suppresses its ability to inhibit protein phosphatase-1 (PP1), but not mutation of Thr-75 or Ser-130.	Serine	215-218	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
19796684-4	2009	Gpr88KOs had normal striatal dopamine D2 receptor density and affinity and DARPP-32 expression but Gpr88KOs had higher basal striatal phosphorylated DARPP-32 Thr-34.	Threonine	158-161	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	149-157
19834457-7	2009	In the striatum of the knock-in mice, DARPP-32 phosphorylation at Thr 34, which is important for the regulation of depression-related behaviour, is increased.	Threonine	66-69	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	38-46
19538708-7	2009	In striatal slices from nNOS KO mice, the effects of a dopamine D1 receptor agonist, SKF81297, on the phosphorylation of DARPP-32 and AMPA receptor subunit GluR1 at protein kinase A sites were enhanced.	SK and F 81297	85-93	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	121-129
19169672-0	2009	Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice.	Caffeine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	140-148
19158668-5	2009	Mutation of the cAMP-dependent phosphorylation site (Thr34) of the 32-kDa dopamine and cAMP-regulated phosphoprotein (DARPP-32) decreased the haloperidol-induced H3 phosphorylation, supporting the role of cAMP in H3 phosphorylation.	Cyclic AMP	16-20	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	118-126
19158668-5	2009	Mutation of the cAMP-dependent phosphorylation site (Thr34) of the 32-kDa dopamine and cAMP-regulated phosphoprotein (DARPP-32) decreased the haloperidol-induced H3 phosphorylation, supporting the role of cAMP in H3 phosphorylation.	Cyclic AMP	87-91	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	118-126
19158668-5	2009	Mutation of the cAMP-dependent phosphorylation site (Thr34) of the 32-kDa dopamine and cAMP-regulated phosphoprotein (DARPP-32) decreased the haloperidol-induced H3 phosphorylation, supporting the role of cAMP in H3 phosphorylation.	Haloperidol	142-153	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	118-126
19158668-5	2009	Mutation of the cAMP-dependent phosphorylation site (Thr34) of the 32-kDa dopamine and cAMP-regulated phosphoprotein (DARPP-32) decreased the haloperidol-induced H3 phosphorylation, supporting the role of cAMP in H3 phosphorylation.	Cyclic AMP	87-91	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	118-126
18923023-7	2008	Rolipram induced a small increase in DARPP-32 Thr34 phosphorylation preferentially in striatopallidal neurons by activating adenosine A(2A) receptor signaling in striatum.	Rolipram	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	37-45
19181855-4	2009	Compared with WT mice, tPA-/- mice injected with cocaine displayed attenuated phosphorylation of ERK, cAMP response element binding protein (CREB), and dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and blunted induction of immediate early genes (IEGs) c-Fos, Egr-1, and Homer 1a in the amygdala and the nucleus accumbens (NAc).	Cocaine	49-56	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	152-201
19181855-4	2009	Compared with WT mice, tPA-/- mice injected with cocaine displayed attenuated phosphorylation of ERK, cAMP response element binding protein (CREB), and dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and blunted induction of immediate early genes (IEGs) c-Fos, Egr-1, and Homer 1a in the amygdala and the nucleus accumbens (NAc).	Cocaine	49-56	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	203-211
18790059-3	2008	We also demonstrate that a mouse strain lacking the dopamine signaling molecule DARPP-32 has significantly reduced levels of both Lrrk2 and alpha-synuclein, while mice carrying a disabling mutation of the DARPP-32 phosphorylation site T34A or lack alpha-synuclein do not show any changes.	Dopamine	52-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	80-88
18657800-8	2008	Levels of phosphorylated cyclic adenosine monophosphate (cAMP) response element binding protein (pCREB), brain-derived neurotrophic factor (BDNF), and dopamine and cyclic adenosine monophosphate regulated phosphoprotein with a molecular mass of 32 kDa (DARPP-32) in the nucleus accumbens were reduced in Delta FosB mice, suggestive of reduced dopamine signaling.	Cyclic AMP	164-194	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	253-261
18823371-5	2008	Treatment with SKF83959 or SKF83822 increased DARPP-32 phosphorylation.	SK and F 83959	15-23	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	46-54
18823371-5	2008	Treatment with SKF83959 or SKF83822 increased DARPP-32 phosphorylation.	3-allyl-6-chloro-7,8-dihydroxy-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine	27-35	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	46-54
18823371-6	2008	The SKF83959- and SKF83822-induced increase in DARPP-32 phosphorylation was largely, but partially, antagonized by a D(1) receptor antagonist, SCH23390, and the residual SCH23390-insensitive increase was abolished by an adenosine A(2A) receptor antagonist.	SK and F 83959	4-12	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	47-55
18823371-6	2008	The SKF83959- and SKF83822-induced increase in DARPP-32 phosphorylation was largely, but partially, antagonized by a D(1) receptor antagonist, SCH23390, and the residual SCH23390-insensitive increase was abolished by an adenosine A(2A) receptor antagonist.	3-allyl-6-chloro-7,8-dihydroxy-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine	18-26	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	47-55
18823371-6	2008	The SKF83959- and SKF83822-induced increase in DARPP-32 phosphorylation was largely, but partially, antagonized by a D(1) receptor antagonist, SCH23390, and the residual SCH23390-insensitive increase was abolished by an adenosine A(2A) receptor antagonist.	SCH 23390	143-151	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	47-55
18823371-6	2008	The SKF83959- and SKF83822-induced increase in DARPP-32 phosphorylation was largely, but partially, antagonized by a D(1) receptor antagonist, SCH23390, and the residual SCH23390-insensitive increase was abolished by an adenosine A(2A) receptor antagonist.	SCH 23390	170-178	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	47-55
18823371-7	2008	In addition, the SKF83959-induced, SCH23390-sensitive increase in DARPP-32 phosphorylation was enhanced by a PLC inhibitor.	SK and F 83959	17-25	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	66-74
18823371-7	2008	In addition, the SKF83959-induced, SCH23390-sensitive increase in DARPP-32 phosphorylation was enhanced by a PLC inhibitor.	SCH 23390	35-43	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	66-74
18923023-8	2008	In contrast, the PDE10A inhibitor, papaverine, had no effect on TH phosphorylation or dopamine turnover, but instead robustly increased DARPP-32 Thr34 and GluR1 Ser845 phosphorylation in striatal neurons.	Papaverine	35-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	136-144
18554320-0	2008	Enhanced CREB and DARPP-32 phosphorylation in the nucleus accumbens and CREB, ERK, and GluR1 phosphorylation in the dorsal hippocampus is associated with cocaine-conditioned place preference behavior.	Cocaine	154-161	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	18-26
18622401-2	2008	The phosphorylation of DARPP-32 at threonine 34 is essential for mediating the effects of both psychostimulant and antipsychotic drugs; however, these drugs are known to have opposing behavioral and clinical effects.	Threonine	35-44	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	23-31
18622401-5	2008	Using this new methodology, we found that cocaine, a psychostimulant, and haloperidol, a sedation-producing antipsychotic, exert differential effects on DARPP-32 phosphorylation in the two neuronal populations that can explain their opposing behavioral effects.	Cocaine	42-49	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	153-161
18622401-5	2008	Using this new methodology, we found that cocaine, a psychostimulant, and haloperidol, a sedation-producing antipsychotic, exert differential effects on DARPP-32 phosphorylation in the two neuronal populations that can explain their opposing behavioral effects.	Haloperidol	74-85	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	153-161
18614680-7	2008	In both wild-type and DARPP-32 knock-out mice, Drd1a robustly induces pERK1/2 throughout the dopamine-depleted striatum.	Dopamine	93-101	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	22-30
18554320-3	2008	To better understand the mechanism of cocaine-conditioned place preference we have used western blot analysis to examine changes in phosphorylation of cAMP-response element binding protein (CREB), dopamine- and cyclic AMP-regulated phosphoprotein 32 (DARPP-32), extracellular signal-regulated kinase (ERK) and GluR1, key molecular substrates altered by cocaine, in the nucleus accumbens (NAc) and dorsal hippocampus (DHC) of C57BL/6 mice.	Cocaine	38-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	251-259
18554320-4	2008	Our studies revealed that re-exposing mice to an environment in which they were previously given cocaine resulted in increased levels of Ser133 phospho-CREB and Thr34 phospho-DARPP-32 with a corresponding decrease in Thr75 phospho-DARPP-32 in the NAc.	Cocaine	97-104	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	175-183
18554320-4	2008	Our studies revealed that re-exposing mice to an environment in which they were previously given cocaine resulted in increased levels of Ser133 phospho-CREB and Thr34 phospho-DARPP-32 with a corresponding decrease in Thr75 phospho-DARPP-32 in the NAc.	Cocaine	97-104	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	231-239
18554320-6	2008	These data suggest that the formation of contextual drug reward associations involves recruitment of the DHC-NAc circuit with activation of the DARPP-32/CREB pathway in the NAc and the ERK/CREB pathway in the DHC.	dhc	105-108	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	144-152
17251906-0	2007	Activation of the cAMP/PKA/DARPP-32 signaling pathway is required for morphine psychomotor stimulation but not for morphine reward.	Cyclic AMP	18-22	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	27-35
17693396-6	2008	Low concentrations of DA (100 nM) increased interneuron excitability via D1 receptors, protein kinase A, and cyclic adenosine 3",5"-monophosphate in slices from both normal and DARPP-32 KO mice.	Dopamine	22-24	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	177-185
18190909-3	2008	Treatment of acute striatal slices with a PKC-activating phorbol ester caused a time- and dose-dependent decrease in the levels of phospho-Ser6 inhibitor-1, phospho-Ser67 inhibitor-1, and phospho-Thr75 dopamine- and cAMP-regulated phosphoprotein, Mr 32,000 (DARPP-32).	Phorbol Esters	57-70	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	202-256
18190909-3	2008	Treatment of acute striatal slices with a PKC-activating phorbol ester caused a time- and dose-dependent decrease in the levels of phospho-Ser6 inhibitor-1, phospho-Ser67 inhibitor-1, and phospho-Thr75 dopamine- and cAMP-regulated phosphoprotein, Mr 32,000 (DARPP-32).	Phorbol Esters	57-70	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	258-266
18155847-1	2008	The roles of dopamine and cyclic-AMP regulated phosphoprotein-32 (DARPP-32) in mediating dopamine (DA)-dependent modulation of corticoaccumbens transmission and intercellular coupling were examined in mouse accumbens (NAC) neurons by both intracellular sharp electrode and whole cell recordings.	Cyclic AMP	26-36	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	66-74
18155847-1	2008	The roles of dopamine and cyclic-AMP regulated phosphoprotein-32 (DARPP-32) in mediating dopamine (DA)-dependent modulation of corticoaccumbens transmission and intercellular coupling were examined in mouse accumbens (NAC) neurons by both intracellular sharp electrode and whole cell recordings.	Dopamine	89-97	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	66-74
18155847-2	2008	In wild-type (WT) mice bath application of the D2-like agonist quinpirole resulted in 73% coupling incidence in NAC spiny neurons, compared with baseline (9%), whereas quinpirole failed to affect the basal coupling (24%) in slices from DARPP-32 knockout (KO) mice.	Quinpirole	63-73	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	236-244
18032663-8	2007	Stimulation of the D1 receptor induced phosphorylation of dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34 in striatal slices, and the addition of indomethacin, a PG synthesis inhibitor, attenuated the D1 agonist-induced increase in DARPP-32-Thr34 phosphorylation.	Indomethacin	171-183	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	58-110
18032663-8	2007	Stimulation of the D1 receptor induced phosphorylation of dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34 in striatal slices, and the addition of indomethacin, a PG synthesis inhibitor, attenuated the D1 agonist-induced increase in DARPP-32-Thr34 phosphorylation.	Indomethacin	171-183	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-120
18032663-8	2007	Stimulation of the D1 receptor induced phosphorylation of dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34 in striatal slices, and the addition of indomethacin, a PG synthesis inhibitor, attenuated the D1 agonist-induced increase in DARPP-32-Thr34 phosphorylation.	Indomethacin	171-183	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	257-265
18032663-8	2007	Stimulation of the D1 receptor induced phosphorylation of dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34 in striatal slices, and the addition of indomethacin, a PG synthesis inhibitor, attenuated the D1 agonist-induced increase in DARPP-32-Thr34 phosphorylation.	pg	187-189	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	58-110
18032663-8	2007	Stimulation of the D1 receptor induced phosphorylation of dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34 in striatal slices, and the addition of indomethacin, a PG synthesis inhibitor, attenuated the D1 agonist-induced increase in DARPP-32-Thr34 phosphorylation.	pg	187-189	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-120
17826804-6	2007	Isoflurane and ketamine also reduced phosphorylation of spinophilin at S94, but oppositely regulated phosphorylation of presynaptic (tyrosine hydroxylase) and postsynaptic (DARPP-32) markers of dopaminergic neurotransmission in striatum.	Isoflurane	0-10	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	173-181
17826804-6	2007	Isoflurane and ketamine also reduced phosphorylation of spinophilin at S94, but oppositely regulated phosphorylation of presynaptic (tyrosine hydroxylase) and postsynaptic (DARPP-32) markers of dopaminergic neurotransmission in striatum.	Ketamine	15-23	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	173-181
18086127-7	2008	Furthermore, it normalized DARPP-32 expression of the 32 kDa dopamine and cAMP-regulated phosphoprotein, increased the number of enkephalin-containing boutons, and reduced formation of neuronal intranuclear inclusions in the striatum of R6/1 mice.	Dopamine	61-69	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	27-35
18086127-7	2008	Furthermore, it normalized DARPP-32 expression of the 32 kDa dopamine and cAMP-regulated phosphoprotein, increased the number of enkephalin-containing boutons, and reduced formation of neuronal intranuclear inclusions in the striatum of R6/1 mice.	Cyclic AMP	74-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	27-35
18234897-8	2008	DARPP-32 protein levels were significantly upregulated in the lateral region of the caudate-putamen exclusively in postweanling mice after chronic cocaine.	Cocaine	147-154	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
18234897-9	2008	Daily pretreatment with K252a attenuated the induction of DARPP-32 in the postweanling striatum.	staurosporine aglycone	24-29	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	58-66
17251906-0	2007	Activation of the cAMP/PKA/DARPP-32 signaling pathway is required for morphine psychomotor stimulation but not for morphine reward.	Morphine	70-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	27-35
17251906-2	2007	Here, we show that, in the mouse nucleus accumbens and dorsal striatum, acute administration of morphine resulted in an increase in the state of phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34, without affecting phosphorylation at Thr75.	Morphine	96-104	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	168-221
17251906-2	2007	Here, we show that, in the mouse nucleus accumbens and dorsal striatum, acute administration of morphine resulted in an increase in the state of phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) at Thr34, without affecting phosphorylation at Thr75.	Morphine	96-104	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	223-231
17251906-4	2007	DARPP-32 knockout mice and T34A DARPP-32 mutant mice displayed a lower hyperlocomotor response to a single injection of morphine than wild-type controls.	Morphine	120-128	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
17251906-4	2007	DARPP-32 knockout mice and T34A DARPP-32 mutant mice displayed a lower hyperlocomotor response to a single injection of morphine than wild-type controls.	Morphine	120-128	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	32-40
17251906-5	2007	In contrast, in T75A DARPP-32 mutant mice, morphine-induced psychomotor activation was indistinguishable from that of wild-type littermates.	Morphine	43-51	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	21-29
17251906-6	2007	In spite of their reduced response to the acute hyperlocomotor effect of morphine, DARPP-32 knockout mice and T34A DARPP-32 mutant mice were able to develop behavioral sensitization to morphine comparable to that of wild-type controls and to display morphine conditioned place preference.	Morphine	185-193	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	83-91
17251906-6	2007	In spite of their reduced response to the acute hyperlocomotor effect of morphine, DARPP-32 knockout mice and T34A DARPP-32 mutant mice were able to develop behavioral sensitization to morphine comparable to that of wild-type controls and to display morphine conditioned place preference.	Morphine	185-193	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	115-123
17251906-6	2007	In spite of their reduced response to the acute hyperlocomotor effect of morphine, DARPP-32 knockout mice and T34A DARPP-32 mutant mice were able to develop behavioral sensitization to morphine comparable to that of wild-type controls and to display morphine conditioned place preference.	Morphine	185-193	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	83-91
17251906-6	2007	In spite of their reduced response to the acute hyperlocomotor effect of morphine, DARPP-32 knockout mice and T34A DARPP-32 mutant mice were able to develop behavioral sensitization to morphine comparable to that of wild-type controls and to display morphine conditioned place preference.	Morphine	185-193	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	115-123
17251906-7	2007	These results demonstrate that dopamine D1 receptor-mediated activation of the cAMP/DARPP-32 cascade in striatal medium spiny neurons is involved in the psychomotor action, but not in the rewarding properties, of morphine.	Cyclic AMP	79-83	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	84-92
17251906-7	2007	These results demonstrate that dopamine D1 receptor-mediated activation of the cAMP/DARPP-32 cascade in striatal medium spiny neurons is involved in the psychomotor action, but not in the rewarding properties, of morphine.	Morphine	213-221	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	84-92
17596448-8	2007	Together, these results indicate that a significant proportion of the abnormal involuntary movements developed in response to chronic L-DOPA are attributable to hyperactivation in striatal medium spiny neurons of a signaling pathway including sequential phosphorylation of DARPP-32, ERK1/2, MSK-1, and histone H3.	Levodopa	134-140	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	273-281
17596448-0	2007	Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.	Levodopa	101-107	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	29-37
17596448-2	2007	We show that attenuation of cAMP signaling in the medium spiny neurons of the striatum, achieved by genetic inactivation of the dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), reduces LID.	Cyclic AMP	28-32	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	128-180
17596448-2	2007	We show that attenuation of cAMP signaling in the medium spiny neurons of the striatum, achieved by genetic inactivation of the dopamine and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), reduces LID.	Cyclic AMP	28-32	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	182-190
17596448-3	2007	We also show that, in dyskinetic mice, sensitized cAMP/cAMP-dependent protein kinase/DARPP-32 signaling leads to phosphorylation/activation of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2).	Cyclic AMP	50-54	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	85-93
17596448-3	2007	We also show that, in dyskinetic mice, sensitized cAMP/cAMP-dependent protein kinase/DARPP-32 signaling leads to phosphorylation/activation of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2).	Cyclic AMP	55-59	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	85-93
17428998-6	2007	EMDT increased the phosphorylation states of Thr34-DARPP-32 and Ser845-GluR1, both in brain slices and in the intact brain, which were effects also seen with the antidepressant fluoxetine; as with fluoxetine, these effects were demonstrated to be independent of D1 receptor stimulation.	Fluoxetine	177-187	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	51-59
17552992-1	2007	The goal of the present study was to elucidate the role of DARPP-32 (dopamine- and cyclic adenosine 3"-5"-monophosphate-regulated phosphoprotein, 32 kDa) in retinal function.	Dopamine	69-77	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	59-67
17552992-1	2007	The goal of the present study was to elucidate the role of DARPP-32 (dopamine- and cyclic adenosine 3"-5"-monophosphate-regulated phosphoprotein, 32 kDa) in retinal function.	Cyclic AMP	83-119	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	59-67
17552992-5	2007	Using mice entrained to a 12-12 h light-dark cycle, we found that exposure to light presented during the dark phase significantly enhanced phosphorylation of DARPP-32 at threonine (Thr) 34 and phosphorylation of the ionotropic glutamate receptor subunit GluR1 at serine (Ser) 845, as measured by immunoblots.	Threonine	170-179	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	158-166
17552992-5	2007	Using mice entrained to a 12-12 h light-dark cycle, we found that exposure to light presented during the dark phase significantly enhanced phosphorylation of DARPP-32 at threonine (Thr) 34 and phosphorylation of the ionotropic glutamate receptor subunit GluR1 at serine (Ser) 845, as measured by immunoblots.	Threonine	181-184	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	158-166
17552992-5	2007	Using mice entrained to a 12-12 h light-dark cycle, we found that exposure to light presented during the dark phase significantly enhanced phosphorylation of DARPP-32 at threonine (Thr) 34 and phosphorylation of the ionotropic glutamate receptor subunit GluR1 at serine (Ser) 845, as measured by immunoblots.	Serine	263-269	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	158-166
17552992-5	2007	Using mice entrained to a 12-12 h light-dark cycle, we found that exposure to light presented during the dark phase significantly enhanced phosphorylation of DARPP-32 at threonine (Thr) 34 and phosphorylation of the ionotropic glutamate receptor subunit GluR1 at serine (Ser) 845, as measured by immunoblots.	Serine	271-274	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	158-166
17552992-6	2007	However, light also increased Ser 845-GluR1 phosphorylation in DARPP-32-knockout mice.	Serine	30-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	63-71
17552992-7	2007	When a dopamine D1 receptor antagonist was injected into the eye prior to light exposure, phosphorylation of both Thr 34-DARPP-32 and Ser 845-GluR1 was significantly reduced.	Threonine	114-117	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	121-129
17552992-8	2007	These data indicate that DARPP-32 participates in dopamine-mediated modifications of retinal function.	Dopamine	50-58	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	25-33
17552992-9	2007	We also tested for a possible circadian rhythm of Thr 34- and Thr 75-DARPP-32 and Ser 845-GluR1 expression.	Threonine	62-65	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	69-77
17010100-0	2006	Phosphodiesterase 1B differentially modulates the effects of methamphetamine on locomotor activity and spatial learning through DARPP32-dependent pathways: evidence from PDE1B-DARPP32 double-knockout mice.	Methamphetamine	61-76	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	128-135
16954211-1	2006	Recent investigations have shown that three major striatal-signaling pathways (protein kinase A/DARPP-32, Akt/glycogen synthase kinase 3, and ERK) are involved in the regulation of locomotor activity by the monoaminergic neurotransmitter dopamine.	Dopamine	238-246	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	96-104
17010100-1	2006	Mice lacking phosphodiesterase 1B (PDE1B) exhibit an exaggerated locomotor response to D-methamphetamine and increased in vitro phosphorylation of DARPP32 (dopamine- and cAMP-regulated phosphoprotein, M r 32 kDa) at Thr34 in striatal brain slices treated with the D1 receptor agonist, SKF81297.	Cyclic AMP	170-174	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-154
17081696-3	2007	QUIN injection induced a decrease in dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) protein levels that was higher in NT-3 +/- than in BDNF+/- or wild type animals.	Quinolinic Acid	0-4	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	37-96
17081696-3	2007	QUIN injection induced a decrease in dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) protein levels that was higher in NT-3 +/- than in BDNF+/- or wild type animals.	Quinolinic Acid	0-4	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	98-106
17010100-1	2006	Mice lacking phosphodiesterase 1B (PDE1B) exhibit an exaggerated locomotor response to D-methamphetamine and increased in vitro phosphorylation of DARPP32 (dopamine- and cAMP-regulated phosphoprotein, M r 32 kDa) at Thr34 in striatal brain slices treated with the D1 receptor agonist, SKF81297.	SK and F 81297	285-293	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-154
17010100-1	2006	Mice lacking phosphodiesterase 1B (PDE1B) exhibit an exaggerated locomotor response to D-methamphetamine and increased in vitro phosphorylation of DARPP32 (dopamine- and cAMP-regulated phosphoprotein, M r 32 kDa) at Thr34 in striatal brain slices treated with the D1 receptor agonist, SKF81297.	Dopamine	156-164	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-154
16750892-5	2006	An A(1) receptor agonist, 2-chloro-N(6)-cyclopentyladenosine (100 nM), caused a transient increase, followed by a transient decrease, in DARPP-32 Thr34 phosphorylation.	2-chloro-N(6)cyclopentyladenosine	26-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	137-145
17010100-4	2006	Analysis of the response to d-methamphetamine on locomotor activity showed that the hyperactivity experienced by PDE1B mutant mice was blocked in PDE1B-/- x DARPP32-/- double-KO mice, consistent with participation of PDE1B and DARPP32 in the same pathway.	Methamphetamine	28-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	157-164
17010100-4	2006	Analysis of the response to d-methamphetamine on locomotor activity showed that the hyperactivity experienced by PDE1B mutant mice was blocked in PDE1B-/- x DARPP32-/- double-KO mice, consistent with participation of PDE1B and DARPP32 in the same pathway.	Methamphetamine	28-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	227-234
16971527-1	2006	The multifunctional regulator of protein kinases and phosphatases dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) is an important molecular target of the dopamine signaling pathway.	Dopamine	66-74	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	121-129
16750892-2	2006	Adenosine acting on A(2A) receptors increases the phosphorylation of dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) at Thr34 (the cAMP-dependent protein kinase [PKA] site) in striatopallidal neurons, and opposes dopamine D2 receptor signaling.	Adenosine	0-9	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	129-137
16750892-2	2006	Adenosine acting on A(2A) receptors increases the phosphorylation of dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) at Thr34 (the cAMP-dependent protein kinase [PKA] site) in striatopallidal neurons, and opposes dopamine D2 receptor signaling.	Dopamine	69-77	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	129-137
16750892-2	2006	Adenosine acting on A(2A) receptors increases the phosphorylation of dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) at Thr34 (the cAMP-dependent protein kinase [PKA] site) in striatopallidal neurons, and opposes dopamine D2 receptor signaling.	Cyclic AMP	83-87	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	129-137
16123776-0	2006	Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action.	Threonine	31-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
16750892-2	2006	Adenosine acting on A(2A) receptors increases the phosphorylation of dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa (DARPP-32) at Thr34 (the cAMP-dependent protein kinase [PKA] site) in striatopallidal neurons, and opposes dopamine D2 receptor signaling.	Cyclic AMP	153-157	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	129-137
16525043-0	2006	Cocaine self-administration in mice is inversely related to phosphorylation at Thr34 (protein kinase A site) and Ser130 (kinase CK1 site) of DARPP-32.	Cocaine	0-7	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	141-149
16525043-2	2006	The phosphoprotein DARPP-32 (dopamine- and cAMP-regulated phosphoprotein) has been shown to mediate the intracellular events after activation of dopamine receptors.	Dopamine	29-37	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
16525043-2	2006	The phosphoprotein DARPP-32 (dopamine- and cAMP-regulated phosphoprotein) has been shown to mediate the intracellular events after activation of dopamine receptors.	Cyclic AMP	43-47	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
16525043-6	2006	Both Thr34A- and Ser130A-DARPP-32 mutant mice self-administered more cocaine than their respective wild-type controls.	Cocaine	69-76	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	25-33
16525043-7	2006	Also, cocaine-induced increases of dopamine in dorsal striatum were attenuated in the Thr34A- and Ser130A-DARPP-32 phosphomutant mice compared with wild-type mice.	Cocaine	6-13	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
16525043-7	2006	Also, cocaine-induced increases of dopamine in dorsal striatum were attenuated in the Thr34A- and Ser130A-DARPP-32 phosphomutant mice compared with wild-type mice.	Dopamine	35-43	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
16525043-8	2006	Notably, levels of P-Thr34- and P-Ser130-DARPP-32 were reduced after self-administration of cocaine in wild-type mice.	Cocaine	92-99	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	41-49
16525043-9	2006	Thus, phosphorylation states of Thr34- and Ser130-DARPP-32 play important roles in modulating the reinforcing effects of cocaine.	Cocaine	121-128	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	50-58
16123776-0	2006	Phosphorylation of DARPP-32 at Threonine-34 is required for cocaine action.	Cocaine	60-67	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
16123776-1	2006	Mice lacking DARPP-32, a striatal-enriched phosphoprotein, show abnormal behavioral and biochemical responses to cocaine, but the role of individual phosphorylation sites in DARPP-32 in these responses is unknown.	Cocaine	113-120	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	13-21
16123776-2	2006	We show here that mutation of Thr-34 in DARPP-32 mimicked the behavioral phenotype of the constitutive DARPP-32 knockout in cocaine-induced place conditioning, locomotor activity, and sensitization paradigms.	Threonine	30-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	40-48
16123776-2	2006	We show here that mutation of Thr-34 in DARPP-32 mimicked the behavioral phenotype of the constitutive DARPP-32 knockout in cocaine-induced place conditioning, locomotor activity, and sensitization paradigms.	Threonine	30-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	103-111
16123776-2	2006	We show here that mutation of Thr-34 in DARPP-32 mimicked the behavioral phenotype of the constitutive DARPP-32 knockout in cocaine-induced place conditioning, locomotor activity, and sensitization paradigms.	Cocaine	124-131	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	40-48
16123776-2	2006	We show here that mutation of Thr-34 in DARPP-32 mimicked the behavioral phenotype of the constitutive DARPP-32 knockout in cocaine-induced place conditioning, locomotor activity, and sensitization paradigms.	Cocaine	124-131	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	103-111
16123776-4	2006	Consistent with these behavioral findings, we found that cocaine regulation of gene expression in striatum, including the acute induction of the immediate early genes c-fos and arc (activity-regulated cytoskeletal-associated gene), was abolished in DARPP-32 Thr-34 mutants, but not in Thr-75 mutants.	Cocaine	57-64	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	249-257
16123776-4	2006	Consistent with these behavioral findings, we found that cocaine regulation of gene expression in striatum, including the acute induction of the immediate early genes c-fos and arc (activity-regulated cytoskeletal-associated gene), was abolished in DARPP-32 Thr-34 mutants, but not in Thr-75 mutants.	Threonine	258-261	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	249-257
16123776-4	2006	Consistent with these behavioral findings, we found that cocaine regulation of gene expression in striatum, including the acute induction of the immediate early genes c-fos and arc (activity-regulated cytoskeletal-associated gene), was abolished in DARPP-32 Thr-34 mutants, but not in Thr-75 mutants.	Threonine	285-288	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	249-257
16123776-6	2006	These findings highlight distinct roles of the Thr-34 and Thr-75 phosphorylation sites of DARPP-32 in mediating short- and long-term behavioral and biochemical actions of cocaine.	Threonine	47-50	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	90-98
16123776-6	2006	These findings highlight distinct roles of the Thr-34 and Thr-75 phosphorylation sites of DARPP-32 in mediating short- and long-term behavioral and biochemical actions of cocaine.	Threonine	58-61	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	90-98
16084497-0	2005	DARPP-32 phosphorylation opposes the behavioral effects of nicotine.	Nicotine	59-67	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
16336634-8	2006	The increase in Ser845 phosphorylation produced by haloperidol is abolished in dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) knockout mice, or in mice in which the PKA phosphorylation site on DARPP-32 (i.e. Thr34) has been mutated (Thr34-->Ala mutant mice), and requires tonic activation of adenosine A2A receptors.	Haloperidol	51-62	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	79-132
16336634-8	2006	The increase in Ser845 phosphorylation produced by haloperidol is abolished in dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) knockout mice, or in mice in which the PKA phosphorylation site on DARPP-32 (i.e. Thr34) has been mutated (Thr34-->Ala mutant mice), and requires tonic activation of adenosine A2A receptors.	Haloperidol	51-62	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	134-142
16336634-8	2006	The increase in Ser845 phosphorylation produced by haloperidol is abolished in dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) knockout mice, or in mice in which the PKA phosphorylation site on DARPP-32 (i.e. Thr34) has been mutated (Thr34-->Ala mutant mice), and requires tonic activation of adenosine A2A receptors.	Haloperidol	51-62	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	211-219
16336634-9	2006	These results demonstrate that dopamine D2 antagonists increase GluR1 phosphorylation at Ser845 by removing the inhibitory tone exerted by dopamine D2 receptors on the PKA/DARPP-32 cascade.	Dopamine	31-39	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	172-180
16084497-2	2005	Because post-synaptic neurons within the striatum contain high levels of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), we hypothesized that DARPP-32 may functionally contribute to the behavioral effects of nicotine.	Nicotine	230-238	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	77-130
16084497-2	2005	Because post-synaptic neurons within the striatum contain high levels of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), we hypothesized that DARPP-32 may functionally contribute to the behavioral effects of nicotine.	Nicotine	230-238	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	132-140
16084497-2	2005	Because post-synaptic neurons within the striatum contain high levels of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32), we hypothesized that DARPP-32 may functionally contribute to the behavioral effects of nicotine.	Nicotine	230-238	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	164-172
16084497-6	2005	The phosphorylation of DARPP-32 at threonine34 and threonine75 were examined using Western blotting.	threonine34	35-46	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	23-31
16084497-9	2005	Systemic injections of nicotine resulted in increased striatal DARPP-32 phosphorylation at threonine34 and threonine75.	Nicotine	23-31	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	63-71
16084497-9	2005	Systemic injections of nicotine resulted in increased striatal DARPP-32 phosphorylation at threonine34 and threonine75.	threonine34	91-102	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	63-71
16084497-10	2005	CONCLUSIONS: DARPP-32 opposes the behavioral effects of nicotine possibly via concurrent phosphorylation at the two threonine sites.	Nicotine	56-64	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	13-21
16084497-10	2005	CONCLUSIONS: DARPP-32 opposes the behavioral effects of nicotine possibly via concurrent phosphorylation at the two threonine sites.	Threonine	116-125	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	13-21
15665076-5	2005	Increased Cdk5-mediated phosphorylation of dopamine and cAMP-regulated phosphoprotein, molecular mass 32 kDa (DARPP-32) at Thr-75, was accompanied by decreased phosphorylation of DARPP-32 at Thr-34.	Dopamine	43-51	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	110-118
15770104-0	2005	Effect of ethanol on DARPP-32 phosphorylation in transgenic mice that express human type VII adenylyl cyclase in brain.	Ethanol	10-17	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	21-29
15770104-1	2005	BACKGROUND: Dopamine and cyclic adenosine monophosphate-regulated phosphoprotein of molecular weight 32 kDa (DARPP-32) is a bidirectional signaling protein found in dopaminergically innervated brain areas.	Dopamine	12-20	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	109-117
15770104-3	2005	Phosphorylation of DARPP-32 on threonine-34 (T34) is regulated through the activation of dopamine (D1) receptors and stimulation of adenylyl cyclase (AC) and protein kinase A activity and by calcineurin.	Threonine	31-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
15770104-4	2005	Phosphorylation of DARPP-32 on threonine-75 (T75) is regulated by cyclin-dependent kinase 5 and protein phosphatase 2A.	Threonine	31-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
15770104-5	2005	DARPP-32 has been implicated in the motivational effects of ethanol.	Ethanol	60-67	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
15770104-6	2005	METHODS: The authors characterized transgenic mice that overexpress an ethanol-sensitive isoform of AC (AC7) in brain by measuring basal and ethanol-modulated DARPP-32 phosphorylation.	Ethanol	71-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	159-167
15770104-6	2005	METHODS: The authors characterized transgenic mice that overexpress an ethanol-sensitive isoform of AC (AC7) in brain by measuring basal and ethanol-modulated DARPP-32 phosphorylation.	Ethanol	141-148	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	159-167
15770104-9	2005	Ethanol administration increased T34 DARPP-32 in nucleus accumbens and amygdala (but not in the striatum) of wild-type and transgenic mice (with a greater effect in amygdala of transgenic mice than wild-type mice).	Ethanol	0-7	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	37-45
15770104-10	2005	Ethanol administration increased T75 DARPP-32 in amygdala of only the wild-type mice and in nucleus accumbens and striatum of both the transgenic and wild-type mice.	Ethanol	0-7	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	37-45
15770104-11	2005	CONCLUSIONS: The effect of ethanol on the balance of DARPP-32 phosphorylation, especially in amygdala of wild-type versus transgenic mice, may contribute to differential motivational effects of ethanol in these animals.	Ethanol	27-34	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	53-61
15770104-11	2005	CONCLUSIONS: The effect of ethanol on the balance of DARPP-32 phosphorylation, especially in amygdala of wild-type versus transgenic mice, may contribute to differential motivational effects of ethanol in these animals.	Ethanol	194-201	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	53-61
16181425-8	2005	Cystamine treatment also ameliorated the striatal volume loss and striatal neuronal atrophy observed in these animals, but was unable to prevent motor dysfunction or the down-regulation of dopamine and cyclic adenosine monophsophate-regulated phosphoprotein (DARPP-32) expression in the striatum.	Cystamine	0-9	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	259-267
16189209-2	2005	To examine the role of the dopamine 1 receptor (D1R)/dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) signaling pathway for this maturation, we studied the effects of a D1R agonist on motor activity in weanling and adult wild-type (WT) mice and mice that lack DARPP-32, a key messenger in the D1R signaling pathway.	Cyclic AMP	67-71	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	108-116
15665076-5	2005	Increased Cdk5-mediated phosphorylation of dopamine and cAMP-regulated phosphoprotein, molecular mass 32 kDa (DARPP-32) at Thr-75, was accompanied by decreased phosphorylation of DARPP-32 at Thr-34.	Dopamine	43-51	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	179-187
15665076-5	2005	Increased Cdk5-mediated phosphorylation of dopamine and cAMP-regulated phosphoprotein, molecular mass 32 kDa (DARPP-32) at Thr-75, was accompanied by decreased phosphorylation of DARPP-32 at Thr-34.	Cyclic AMP	56-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	110-118
15665076-5	2005	Increased Cdk5-mediated phosphorylation of dopamine and cAMP-regulated phosphoprotein, molecular mass 32 kDa (DARPP-32) at Thr-75, was accompanied by decreased phosphorylation of DARPP-32 at Thr-34.	Cyclic AMP	56-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	179-187
15665076-5	2005	Increased Cdk5-mediated phosphorylation of dopamine and cAMP-regulated phosphoprotein, molecular mass 32 kDa (DARPP-32) at Thr-75, was accompanied by decreased phosphorylation of DARPP-32 at Thr-34.	Threonine	123-126	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	110-118
15665076-5	2005	Increased Cdk5-mediated phosphorylation of dopamine and cAMP-regulated phosphoprotein, molecular mass 32 kDa (DARPP-32) at Thr-75, was accompanied by decreased phosphorylation of DARPP-32 at Thr-34.	Threonine	191-194	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	110-118
15608059-5	2005	Activation of ERK by d-amphetamine or by widely abused drugs, including cocaine, nicotine, morphine, and Delta(9)-tetrahydrocannabinol was absent in mice lacking dopamine- and cAMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32).	Dextroamphetamine	21-34	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	222-230
15657149-0	2005	Glutamate regulation of DARPP-32 phosphorylation in neostriatal neurons involves activation of multiple signaling cascades.	Glutamic Acid	0-9	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	24-32
15657149-3	2005	Here, we investigated glutamate-dependent signaling cascades in mouse neostriatal slices by analyzing the phosphorylation of DARPP-32 at Thr-34 and Thr-75.	Glutamic Acid	22-31	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	125-133
15657149-3	2005	Here, we investigated glutamate-dependent signaling cascades in mouse neostriatal slices by analyzing the phosphorylation of DARPP-32 at Thr-34 and Thr-75.	Threonine	137-140	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	125-133
15657149-4	2005	Treatment with glutamate (5 mM) caused a complex change in DARPP-32 Thr-34 phosphorylation.	Glutamic Acid	15-24	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	59-67
15657149-4	2005	Treatment with glutamate (5 mM) caused a complex change in DARPP-32 Thr-34 phosphorylation.	Threonine	68-71	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	59-67
15657149-10	2005	Our analysis of DARPP-32 phosphorylation in the neostriatum revealed that glutamate activates at least five different signaling cascades with different time dependencies, resulting in complex regulation of protein kinase and protein phosphatase activities.	Glutamic Acid	74-83	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
15608059-6	2005	The effects of d-amphetamine or cocaine on ERK activation in the striatum, but not in the prefrontal cortex, were prevented by point mutation of Thr-34, a DARPP-32 residue specifically involved in protein phosphatase-1 inhibition.	Threonine	145-148	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	155-163
15608059-5	2005	Activation of ERK by d-amphetamine or by widely abused drugs, including cocaine, nicotine, morphine, and Delta(9)-tetrahydrocannabinol was absent in mice lacking dopamine- and cAMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32).	Cyclic AMP	176-180	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	222-230
15608059-6	2005	The effects of d-amphetamine or cocaine on ERK activation in the striatum, but not in the prefrontal cortex, were prevented by point mutation of Thr-34, a DARPP-32 residue specifically involved in protein phosphatase-1 inhibition.	Dextroamphetamine	15-28	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	155-163
15608059-6	2005	The effects of d-amphetamine or cocaine on ERK activation in the striatum, but not in the prefrontal cortex, were prevented by point mutation of Thr-34, a DARPP-32 residue specifically involved in protein phosphatase-1 inhibition.	Cocaine	32-39	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	155-163
15292232-10	2004	In experiments with MSN from DARPP-32 knock-out mice, we demonstrated a regulatory role of DARPP-32 in dopamine-induced Ca(2+) oscillations.	Dopamine	103-111	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	29-37
15292232-10	2004	In experiments with MSN from DARPP-32 knock-out mice, we demonstrated a regulatory role of DARPP-32 in dopamine-induced Ca(2+) oscillations.	Dopamine	103-111	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	91-99
15312165-4	2004	Nicotine produced dose-dependent responses, with a low concentration (1 microm) causing a sustained decrease in DARPP-32 Thr34 phosphorylation and a high concentration (100 microm) causing a transient increase in DARPP-32 Thr34 phosphorylation.	Nicotine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-120
15372366-2	2004	Here we report that endocrine cells of the ovary express a phosphoprotein, DARPP-32 (dopamine and cyclic AMP-regulated phosphoprotein of Mr 32,000), which integrates signaling molecules in neurons.	Dopamine	85-93	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	75-83
15312165-4	2004	Nicotine produced dose-dependent responses, with a low concentration (1 microm) causing a sustained decrease in DARPP-32 Thr34 phosphorylation and a high concentration (100 microm) causing a transient increase in DARPP-32 Thr34 phosphorylation.	Nicotine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	213-221
15269172-2	2004	Gsh2 mutants exhibit altered ventral telencephalic development, including a smaller striatum with fewer DARPP-32 neurons than wild types.	gsh2	0-4	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	104-112
15269172-10	2004	Indeed, RA supplementation of Gsh2 mutants, during the period of striatal neurogenesis, results in a significant increase in DARPP-32 expression.	Tretinoin	8-10	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	125-133
15269172-10	2004	Indeed, RA supplementation of Gsh2 mutants, during the period of striatal neurogenesis, results in a significant increase in DARPP-32 expression.	gsh2	30-34	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	125-133
14722243-3	2004	To unravel the signaling pathways underlying this trafficking, we studied mice with targeted disruptions of either the gene that encodes the dopamine- and cAMP-regulated phosphoprotein (DARPP-32), a potent and selective inhibitor of protein phosphatase-1, or the protein tyrosine kinase Fyn.	Dopamine	141-149	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-194
15198675-4	2004	We first confirmed that D2LR activates calcineurin in NG108-15 cells by measurement of dephosphorylation of dopamine- and cyclic AMP-regulated phosphoprotein Mr 32 000 (DARPP-32) at threonin 34 by immunoblot analysis with its phospho-specific antibody.	Threonine	182-190	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	108-167
15198675-4	2004	We first confirmed that D2LR activates calcineurin in NG108-15 cells by measurement of dephosphorylation of dopamine- and cyclic AMP-regulated phosphoprotein Mr 32 000 (DARPP-32) at threonin 34 by immunoblot analysis with its phospho-specific antibody.	Threonine	182-190	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	169-177
14769920-9	2004	Using mice with a point mutation of the CDK5 site of the postsynaptic protein DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, molecular mass of 32 kDa), in the absence or in the presence of a dopamine D1 receptor antagonist, we provide evidence that CDK5 inhibitors potentiate dopaminergic transmission at both presynaptic and postsynaptic locations.	Dopamine	88-96	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	78-86
14722243-3	2004	To unravel the signaling pathways underlying this trafficking, we studied mice with targeted disruptions of either the gene that encodes the dopamine- and cAMP-regulated phosphoprotein (DARPP-32), a potent and selective inhibitor of protein phosphatase-1, or the protein tyrosine kinase Fyn.	Cyclic AMP	155-159	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-194
14713295-6	2003	As with MPH, cocaine stimulated DARPP-32 Thr34 phosphorylation in slices from adult, but not from young mice.	Cocaine	13-20	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	32-40
14713295-7	2003	In contrast, a dopamine D1 agonist, SKF81297, regulated DARPP-32 phosphorylation comparably in slices from young and adult mice, as did methamphetamine, a dopamine releaser.	Dopamine	15-23	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	56-64
12956723-2	2003	We have recently reported that neurotensin stimulates the phosphorylation of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa) at Thr34 (PKA-site) by activating dopamine D1-type receptors in neostriatal neurons.	Dopamine	87-95	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	77-85
12865890-1	2003	Congenic (10 backcrosses into C57BL/6J) mutants with targeted gene deletion of DARPP-32, a neuronal phosphoprotein regarded as an essential mediator of the biological effects of dopamine (DA), were assessed phenotypically using an ethologically based approach that resolves all topographies of behavior in the mouse repertoire.	Dopamine	178-186	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	79-87
12865890-3	2003	Following challenge with the nonselective DA receptor agonist apomorphine, low doses were associated with reduced levels of sniffing, grooming, total rearing, and rearing seated in DARPP-32 mutants relative to wildtypes; this would suggest some role for DARPP-32 in mediating the biological effects of presynaptic D(2)-like autoreceptor or inhibitory postsynaptic D(2)-like receptor activation.	Apomorphine	62-73	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	181-189
12865890-3	2003	Following challenge with the nonselective DA receptor agonist apomorphine, low doses were associated with reduced levels of sniffing, grooming, total rearing, and rearing seated in DARPP-32 mutants relative to wildtypes; this would suggest some role for DARPP-32 in mediating the biological effects of presynaptic D(2)-like autoreceptor or inhibitory postsynaptic D(2)-like receptor activation.	Apomorphine	62-73	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	254-262
14529709-5	2003	Accumbens neurons are enriched for dopamine- and cyclic AMP (cAMP)-regulated phosphoprotein, Mr 32,000 (DARPP-32), a potent inhibitor of protein phosphatase 1 (PP1) when phosphorylated by PKA (at Thr(34)).	Dopamine	35-43	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	104-112
14529709-5	2003	Accumbens neurons are enriched for dopamine- and cyclic AMP (cAMP)-regulated phosphoprotein, Mr 32,000 (DARPP-32), a potent inhibitor of protein phosphatase 1 (PP1) when phosphorylated by PKA (at Thr(34)).	Cyclic AMP	49-59	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	104-112
14529709-5	2003	Accumbens neurons are enriched for dopamine- and cyclic AMP (cAMP)-regulated phosphoprotein, Mr 32,000 (DARPP-32), a potent inhibitor of protein phosphatase 1 (PP1) when phosphorylated by PKA (at Thr(34)).	Cyclic AMP	61-65	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	104-112
14529709-5	2003	Accumbens neurons are enriched for dopamine- and cyclic AMP (cAMP)-regulated phosphoprotein, Mr 32,000 (DARPP-32), a potent inhibitor of protein phosphatase 1 (PP1) when phosphorylated by PKA (at Thr(34)).	Threonine	196-199	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	104-112
14529709-6	2003	We tested the hypothesis that the AMPA/KA or NMDA-stimulated dephosphorylation of DARPP-32 via calcineurin, leading to increased PP1 activity and dephosphorylation of GluR1.	N-Methylaspartate	45-49	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	82-90
14529709-7	2003	AMPA or NMDA treatment decreased phospho-Thr(34)-DARPP-32 levels, effects that were blocked by receptor antagonists, or cyclosporin A.	alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid	0-4	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	49-57
14529709-7	2003	AMPA or NMDA treatment decreased phospho-Thr(34)-DARPP-32 levels, effects that were blocked by receptor antagonists, or cyclosporin A.	N-Methylaspartate	8-12	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	49-57
14529709-7	2003	AMPA or NMDA treatment decreased phospho-Thr(34)-DARPP-32 levels, effects that were blocked by receptor antagonists, or cyclosporin A.	phospho-thr	33-44	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	49-57
14529709-9	2003	These data suggest that AMPA- or NMDA-induced dephosphorylation of GluR1 at Ser(845) occurs by a mechanism that is independent of DARPP-32 and PP1, but involves activation of calcineurin.	N-Methylaspartate	33-37	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	130-138
12956723-2	2003	We have recently reported that neurotensin stimulates the phosphorylation of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa) at Thr34 (PKA-site) by activating dopamine D1-type receptors in neostriatal neurons.	Cyclic AMP	101-105	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	77-85
12956723-8	2003	These results indicate that neurotensin stimulates the release of glutamate by activating a hypothesized unidentified neurotensin receptor, resulting in the dephosphorylation of DARPP-32 at Thr75 by activating NMDA and AMPA receptors expressed at medium spiny neurons.	Glutamic Acid	66-75	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	178-186
12802198-4	2003	Moreover, expression of the striatal projection neuron marker, dopamine- and cAMP-regulated phosphoprotein (DARPP-32) was significantly enhanced in neurons cultured on the homotopic glia.	Cyclic AMP	77-81	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	108-116
12871586-6	2003	This opposite regulation was specifically exerted by haloperidol and clozapine on ERK, CREB, and Elk-1 phosphorylation, as both anti-psychotic drugs increased the phosphorylation of the dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the cyclic AMP-dependent protein kinase (PKA) site.	Haloperidol	53-64	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-245
12871586-6	2003	This opposite regulation was specifically exerted by haloperidol and clozapine on ERK, CREB, and Elk-1 phosphorylation, as both anti-psychotic drugs increased the phosphorylation of the dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the cyclic AMP-dependent protein kinase (PKA) site.	Haloperidol	53-64	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	247-255
12871586-6	2003	This opposite regulation was specifically exerted by haloperidol and clozapine on ERK, CREB, and Elk-1 phosphorylation, as both anti-psychotic drugs increased the phosphorylation of the dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the cyclic AMP-dependent protein kinase (PKA) site.	Clozapine	69-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-245
12871586-6	2003	This opposite regulation was specifically exerted by haloperidol and clozapine on ERK, CREB, and Elk-1 phosphorylation, as both anti-psychotic drugs increased the phosphorylation of the dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the cyclic AMP-dependent protein kinase (PKA) site.	Clozapine	69-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	247-255
12805477-0	2003	Dopamine modulation of membrane excitability in striatal spiny neurons is altered in DARPP-32 knockout mice.	Dopamine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	85-93
12466426-0	2002	Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32.	Dopamine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	109-117
12651945-6	2003	In wild-type mice, quinpirole inhibits the increase in DARPP-32 phosphorylation at Thr-34 induced by SKF81297, a dopamine D1 receptor agonist.	SK and F 81297	101-109	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	55-63
12890509-2	2003	Primary neuronal cultures derived from the LGE give rise to neurons expressing the striatal projection neuron markers Islet1 (ISL1) and dopamine and cAMP-regulated phosphoprotein of 32 kilodaltons (DARPP-32) as well as the olfactory bulb interneuron marker Er81.	Cyclic AMP	149-153	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	198-206
12651945-6	2003	In wild-type mice, quinpirole inhibits the increase in DARPP-32 phosphorylation at Thr-34 induced by SKF81297, a dopamine D1 receptor agonist.	Quinpirole	19-29	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	55-63
12651945-6	2003	In wild-type mice, quinpirole inhibits the increase in DARPP-32 phosphorylation at Thr-34 induced by SKF81297, a dopamine D1 receptor agonist.	Threonine	83-86	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	55-63
12466426-10	2002	The DARPP-32 signaling pathway has an important role in D1 modulation of NMDA currents.	N-Methylaspartate	73-77	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	4-12
12068305-4	2002	The regulation of ethanol sensitivity of NMDA receptors by D1 receptors was absent in DARPP-32 knockout mice.	Ethanol	18-25	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	86-94
12223474-1	2002	Previously, we reported that (S)-3,5-dihydroxypenylglycine (DHPG), an agonist for group I metabotropic glutamate receptors (mGluRs), stimulates CK1 and Cdk5 kinase activities in neostriatal neurons, leading to enhanced phosphorylation, respectively, of Ser-137 and Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosphoprotein, 32 kDa).	(s)-3,5-dihydroxypenylglycine	29-58	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	275-283
12223474-1	2002	Previously, we reported that (S)-3,5-dihydroxypenylglycine (DHPG), an agonist for group I metabotropic glutamate receptors (mGluRs), stimulates CK1 and Cdk5 kinase activities in neostriatal neurons, leading to enhanced phosphorylation, respectively, of Ser-137 and Thr-75 of DARPP-32 (dopamine and cAMP-regulated phosphoprotein, 32 kDa).	dhpg	60-64	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	275-283
12181566-0	2002	Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine.	Caffeine	67-75	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	15-23
12181566-3	2002	Here we show that the stimulatory effect of caffeine on motor activity in mice was greatly reduced following genetic deletion of DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein of relative molecular mass 32,000).	Caffeine	44-52	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	129-137
12181566-3	2002	Here we show that the stimulatory effect of caffeine on motor activity in mice was greatly reduced following genetic deletion of DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein of relative molecular mass 32,000).	Dopamine	139-147	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	129-137
12181566-6	2002	In support of a role for DARPP-32 in the action of caffeine, we found that, in striata of intact mice, caffeine increased the state of phosphorylation of DARPP-32 at Thr 75.	Caffeine	51-59	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	25-33
12181566-6	2002	In support of a role for DARPP-32 in the action of caffeine, we found that, in striata of intact mice, caffeine increased the state of phosphorylation of DARPP-32 at Thr 75.	Caffeine	51-59	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	154-162
12181566-6	2002	In support of a role for DARPP-32 in the action of caffeine, we found that, in striata of intact mice, caffeine increased the state of phosphorylation of DARPP-32 at Thr 75.	Caffeine	103-111	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	25-33
12181566-6	2002	In support of a role for DARPP-32 in the action of caffeine, we found that, in striata of intact mice, caffeine increased the state of phosphorylation of DARPP-32 at Thr 75.	Caffeine	103-111	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	154-162
12181566-6	2002	In support of a role for DARPP-32 in the action of caffeine, we found that, in striata of intact mice, caffeine increased the state of phosphorylation of DARPP-32 at Thr 75.	Threonine	166-169	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	154-162
12181566-8	2002	Together, these studies demonstrate the involvement of DARPP-32 and its phosphorylation/dephosphorylation in the stimulant action of caffeine.	Caffeine	133-141	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	55-63
12068305-5	2002	We propose that DARPP-32 mediated blunting of the response to ethanol subsequent to activation of ventral tegmental area dopaminergic neurons initiates molecular alterations that influence synaptic plasticity in this circuit, thereby promoting the development of ethanol reinforcement.	Ethanol	62-69	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
12068305-5	2002	We propose that DARPP-32 mediated blunting of the response to ethanol subsequent to activation of ventral tegmental area dopaminergic neurons initiates molecular alterations that influence synaptic plasticity in this circuit, thereby promoting the development of ethanol reinforcement.	Ethanol	263-270	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
11964556-2	2002	DARPP-32 (dopamine and cyclic adenosine monophosphate-regulated phosphoprotein of approximate molecular weight 32 kDa) is an important regulator of protein phosphatase-1 that in turn regulates a large number of effectors, including the NMDA receptor.	Dopamine	10-18	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
12077213-0	2002	Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning.	Dopamine	124-132	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	84-92
12077213-5	2002	These results indicate that enhancement of cyclic nucleotide signaling by inactivation of PDE1B-mediated cyclic nucleotide hydrolysis plays a significant role in dopaminergic function through the DARPP-32 and related transduction pathways.	Nucleotides, Cyclic	43-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	196-204
12077213-5	2002	These results indicate that enhancement of cyclic nucleotide signaling by inactivation of PDE1B-mediated cyclic nucleotide hydrolysis plays a significant role in dopaminergic function through the DARPP-32 and related transduction pathways.	Nucleotides, Cyclic	105-122	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	196-204
11880651-0	2002	Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).	Fluoxetine	92-102	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	42-50
11880651-0	2002	Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).	Fluoxetine	104-110	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	42-50
11880651-3	2002	Here we show that, in vivo, fluoxetine, given either acutely or chronically, regulates the phosphorylation state of dopamine- and cAMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32) at multiple sites in prefrontal cortex, hippocampus, and striatum.	Fluoxetine	28-38	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	176-184
11880651-3	2002	Here we show that, in vivo, fluoxetine, given either acutely or chronically, regulates the phosphorylation state of dopamine- and cAMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32) at multiple sites in prefrontal cortex, hippocampus, and striatum.	Dopamine	116-124	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	176-184
11880651-3	2002	Here we show that, in vivo, fluoxetine, given either acutely or chronically, regulates the phosphorylation state of dopamine- and cAMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32) at multiple sites in prefrontal cortex, hippocampus, and striatum.	Cyclic AMP	130-134	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	176-184
11880651-4	2002	Acute administration of fluoxetine increases phosphorylation of DARPP-32 at the protein kinase A site, Thr-34, and at the casein kinase-1 site, Ser-137, and decreases phosphorylation at the cyclin-dependent kinase 5 site, Thr-75.	Fluoxetine	24-34	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	64-72
11880651-4	2002	Acute administration of fluoxetine increases phosphorylation of DARPP-32 at the protein kinase A site, Thr-34, and at the casein kinase-1 site, Ser-137, and decreases phosphorylation at the cyclin-dependent kinase 5 site, Thr-75.	Threonine	103-106	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	64-72
11880651-4	2002	Acute administration of fluoxetine increases phosphorylation of DARPP-32 at the protein kinase A site, Thr-34, and at the casein kinase-1 site, Ser-137, and decreases phosphorylation at the cyclin-dependent kinase 5 site, Thr-75.	Threonine	222-225	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	64-72
11880651-7	2002	Both the fluoxetine-mediated increase in AMPA receptor phosphorylation at Ser-845-GluR1 and the beneficial responsiveness to fluoxetine in an animal test of antidepressant efficacy were strongly reduced in DARPP-32 knockout mice, indicating a critical role for this phosphoprotein in the antidepressant actions of fluoxetine.	Fluoxetine	9-19	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	206-214
11880651-7	2002	Both the fluoxetine-mediated increase in AMPA receptor phosphorylation at Ser-845-GluR1 and the beneficial responsiveness to fluoxetine in an animal test of antidepressant efficacy were strongly reduced in DARPP-32 knockout mice, indicating a critical role for this phosphoprotein in the antidepressant actions of fluoxetine.	Serine	74-77	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	206-214
11880651-7	2002	Both the fluoxetine-mediated increase in AMPA receptor phosphorylation at Ser-845-GluR1 and the beneficial responsiveness to fluoxetine in an animal test of antidepressant efficacy were strongly reduced in DARPP-32 knockout mice, indicating a critical role for this phosphoprotein in the antidepressant actions of fluoxetine.	Fluoxetine	125-135	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	206-214
11880651-7	2002	Both the fluoxetine-mediated increase in AMPA receptor phosphorylation at Ser-845-GluR1 and the beneficial responsiveness to fluoxetine in an animal test of antidepressant efficacy were strongly reduced in DARPP-32 knockout mice, indicating a critical role for this phosphoprotein in the antidepressant actions of fluoxetine.	Fluoxetine	125-135	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	206-214
11880651-8	2002	Mice chronically treated with fluoxetine had increased levels of DARPP-32 mRNA and protein and a decreased ability to increase phospho-Ser-137-DARPP-32 and phospho-Ser-831-GluR1.	Fluoxetine	30-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	65-73
11880651-8	2002	Mice chronically treated with fluoxetine had increased levels of DARPP-32 mRNA and protein and a decreased ability to increase phospho-Ser-137-DARPP-32 and phospho-Ser-831-GluR1.	Fluoxetine	30-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	143-151
11880652-3	2002	DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of molecular weight 32,000) is a phosphoprotein that has primarily been characterized in relation to dopaminergic neurotransmission.	Dopamine	10-18	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
11880652-3	2002	DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of molecular weight 32,000) is a phosphoprotein that has primarily been characterized in relation to dopaminergic neurotransmission.	Cyclic AMP	24-28	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
11880652-4	2002	Here we report that serotonin regulates DARPP-32 phosphorylation both in vitro and in vivo.	Serotonin	20-29	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	40-48
11880652-5	2002	Stimulation of 5-hydroxy-tryptamine (5-HT4 and 5-HT6 receptors causes an increased phosphorylation state at Thr34-DARPP-32, the protein kinase A site, and a decreased phosphorylation state at Thr75-DARPP-32, the cyclin-dependent kinase 5 site.	Serotonin	15-35	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	114-122
11880652-5	2002	Stimulation of 5-hydroxy-tryptamine (5-HT4 and 5-HT6 receptors causes an increased phosphorylation state at Thr34-DARPP-32, the protein kinase A site, and a decreased phosphorylation state at Thr75-DARPP-32, the cyclin-dependent kinase 5 site.	Serotonin	15-35	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	198-206
11880652-7	2002	Behavioral and gene transcriptional effects induced by compounds that selectively release serotonin were greatly reduced in DARPP-32 knockout mice.	Serotonin	90-99	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	124-132
11955461-0	2002	Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or Inhibitor 1.	Cocaine	13-20	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	91-99
11955461-6	2002	In contrast, conditioned place preference to cocaine is reduced in mice lacking DARPP-32, I-1, or both phosphoproteins.	Cocaine	45-52	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	80-88
11955461-8	2002	CONCLUSIONS: These data imply that increased PP-1 function as a result of deficits in DARPP-32 or I-1 is sufficient to decrease the rewarding properties of cocaine.	Cocaine	156-163	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	86-94
12064480-2	2002	DARPP-32, a dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa, is phosphorylated on Thr34 by cAMP-dependent protein kinase, resulting in its conversion into a potent inhibitor of protein phosphatase-1 (PP 1).	Dopamine	12-20	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
12064480-2	2002	DARPP-32, a dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa, is phosphorylated on Thr34 by cAMP-dependent protein kinase, resulting in its conversion into a potent inhibitor of protein phosphatase-1 (PP 1).	Cyclic AMP	26-30	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
12064480-9	2002	These results indicate that neurotensin stimulates the release of dopamine from nigrostriatal presynaptic terminals in an NMDA receptor- and AMPA receptor-dependent manner, leading to the increase in DARPP-32 Thr34 phosphorylation.	Dopamine	66-74	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	200-208
12064480-11	2002	Thus, neurotensin, by stimulating the release of dopamine, activates the dopamine D1-receptor/cAMP/PKA/DARPP-32/PP 1 cascade.	Dopamine	49-57	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	103-111
12064480-11	2002	Thus, neurotensin, by stimulating the release of dopamine, activates the dopamine D1-receptor/cAMP/PKA/DARPP-32/PP 1 cascade.	Cyclic AMP	94-98	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	103-111
11964556-9	2002	However, when D1 receptors were blocked, bromocriptine reduced the PKA-mediated phosphorylation of both DARPP-32 and NR1.	Bromocriptine	41-54	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	104-112
10669419-6	2000	P also enhanced phosphorylation of DARPP-32 on threonine 34 in the hypothalamus of mice.	Threonine	47-56	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	35-43
11722604-6	2001	The reduction of dopamine and cAMP regulated phosphoprotein of a molecular weight of 32 kDa (DARPP-32) in R6/2 mice does not provide the resistance, as DA-induced striatal lesions are not reduced in size in DARPP-32 knockout mice.	Cyclic AMP	30-34	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	93-101
11150351-0	2001	Motivational effects of ethanol in DARPP-32 knock-out mice.	Ethanol	24-31	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	35-43
11150351-1	2001	DARPP-32 (dopamine and adenosine 3",5"-monophosphate-regulated phosphoprotein, 32 kDa) is an important component of dopaminergic function in brain areas thought to be important for drug and alcohol addiction.	Dopamine	10-18	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
11150351-1	2001	DARPP-32 (dopamine and adenosine 3",5"-monophosphate-regulated phosphoprotein, 32 kDa) is an important component of dopaminergic function in brain areas thought to be important for drug and alcohol addiction.	adenosine 3"	23-35	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
10854268-1	2000	The role of the dopamine- and cyclic AMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32) in dopaminergic regulation of gene transcription in striatum and globus pallidus was examined.	Dopamine	16-24	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	82-90
10854268-1	2000	The role of the dopamine- and cyclic AMP-regulated phosphoprotein of M(r) 32,000 (DARPP-32) in dopaminergic regulation of gene transcription in striatum and globus pallidus was examined.	Cyclic AMP	30-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	82-90
10854268-6	2000	Moreover, the additive stimulation of SKF 82958 and quinelorane, a D(2) receptor agonist, on c-fos mRNA in globus pallidus was significantly decreased in DARPP-32 and DARPP-32/I-1 knockout mice.	quinelorane	52-63	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	154-162
10854268-6	2000	Moreover, the additive stimulation of SKF 82958 and quinelorane, a D(2) receptor agonist, on c-fos mRNA in globus pallidus was significantly decreased in DARPP-32 and DARPP-32/I-1 knockout mice.	quinelorane	52-63	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	167-175
10677546-0	2000	Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors.	dopamine d1	106-117	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	41-94
10677546-4	2000	A dose-dependent increase in the state of phosphorylation of DARPP-32 occurred in mouse striatum after systemic administration of the D(2) receptor antagonist eticlopride (0.1-2.0 mg/kg).	eticlopride	159-170	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	61-69
10677546-8	2000	SCH 23390, but not SCH 58261, abolished the increase in DARPP-32 caused by cocaine (15 mg/kg).	Cocaine	75-82	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	56-64
10998059-7	2000	Alsterpaullone also inhibits the CDK5/p25-dependent phosphorylation of DARPP-32 in mouse striatum slices in vitro.	alsterpaullone	0-14	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	71-79
10844017-5	2000	The effects of dopamine and psychostimulants on the phosphorylation of GluR1 were attenuated in dopamine and cAMP-regulated phosphoprotein M(r) 32 kDa (DARPP-32) knock-out mice.	Dopamine	15-23	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	152-160
10604473-0	1999	Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons.	Dopamine	46-54	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
10604473-7	1999	Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents.	Dopamine	150-158	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	26-34
10604473-3	1999	DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34.	Dopamine	10-18	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
10604473-7	1999	Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents.	Calcium	234-241	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	26-34
10604473-3	1999	DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34.	Cyclic AMP	23-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
10604473-3	1999	DARPP-32 (dopamine and cyclic AMP-regulated phospho-protein, relative molecular mass 32,000) is converted into an inhibitor of protein phosphatase 1 when it is phosphorylated by protein kinase A (PKA) at threonine 34.	Threonine	204-213	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
10604473-4	1999	We find that DARPP-32 is converted into an inhibitor of PKA when phosphorylated at threonine 75 by cyclin-dependent kinase 5 (Cdk5).	Threonine	83-92	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	13-21
10604473-6	1999	Phospho-Thr 75 DARPP-32 inhibits PKA in vitro by a competitive mechanism.	phospho-thr	0-11	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	15-23
10604473-7	1999	Decreasing phospho-Thr 75 DARPP-32 in striatal slices, either by a Cdk5-specific inhibitor or by using genetically altered mice, results in increased dopamine-induced phosphorylation of PKA substrates and augmented peak voltage-gated calcium currents.	phospho-thr	11-22	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	26-34
10217279-4	1999	Cyclosporin A (5 microM), a calcineurin inhibitor, maximally increased the level of phosphorylated DARPP-32 by 17+/-2-fold.	Cyclosporine	0-13	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	99-107
10383649-1	1999	It is well documented that dopamine and dopamine D1 agonists convert the protein phosphatase-1 inhibitor, DARPP-32, from its dephosphorylated, inactive form into its Thr34-phosphorylated, active form, and that these effects on DARPP-32 constitute essential components of the mechanism by which dopamine and D1 agonists achieve their biological effects.	Dopamine	27-35	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
10383649-1	1999	It is well documented that dopamine and dopamine D1 agonists convert the protein phosphatase-1 inhibitor, DARPP-32, from its dephosphorylated, inactive form into its Thr34-phosphorylated, active form, and that these effects on DARPP-32 constitute essential components of the mechanism by which dopamine and D1 agonists achieve their biological effects.	Dopamine	27-35	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	227-235
10383649-1	1999	It is well documented that dopamine and dopamine D1 agonists convert the protein phosphatase-1 inhibitor, DARPP-32, from its dephosphorylated, inactive form into its Thr34-phosphorylated, active form, and that these effects on DARPP-32 constitute essential components of the mechanism by which dopamine and D1 agonists achieve their biological effects.	Dopamine	40-48	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
10383649-1	1999	It is well documented that dopamine and dopamine D1 agonists convert the protein phosphatase-1 inhibitor, DARPP-32, from its dephosphorylated, inactive form into its Thr34-phosphorylated, active form, and that these effects on DARPP-32 constitute essential components of the mechanism by which dopamine and D1 agonists achieve their biological effects.	Dopamine	40-48	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	227-235
10383649-1	1999	It is well documented that dopamine and dopamine D1 agonists convert the protein phosphatase-1 inhibitor, DARPP-32, from its dephosphorylated, inactive form into its Thr34-phosphorylated, active form, and that these effects on DARPP-32 constitute essential components of the mechanism by which dopamine and D1 agonists achieve their biological effects.	Dopamine	40-48	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	106-114
10383649-1	1999	It is well documented that dopamine and dopamine D1 agonists convert the protein phosphatase-1 inhibitor, DARPP-32, from its dephosphorylated, inactive form into its Thr34-phosphorylated, active form, and that these effects on DARPP-32 constitute essential components of the mechanism by which dopamine and D1 agonists achieve their biological effects.	Dopamine	40-48	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	227-235
10383649-2	1999	In contrast to dopamine and D1 agonists, dopamine D2 agonists dephosphorylate and inactivate DARPP-32.	Dopamine	41-49	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	93-101
10383649-5	1999	We have found that dopamine D1 agonists and dopamine D2 agonists inhibit Na+,K+-ATPase activity in dissociated cells from the mouse neostriatum and that, in each case, the effect is abolished in cells from mice deficient in DARPP-32.	Dopamine	19-27	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	224-232
10383649-5	1999	We have found that dopamine D1 agonists and dopamine D2 agonists inhibit Na+,K+-ATPase activity in dissociated cells from the mouse neostriatum and that, in each case, the effect is abolished in cells from mice deficient in DARPP-32.	Dopamine	44-52	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	224-232
10377350-4	1999	In this study we found that DARPP-32 is expressed in <12% of E13- or E17-derived striatal neurons when they are grown in defined media at high or low density in serum, dopamine, or Neurobasal/N2 (Life Technologies), and ARPP-21 is expressed in <1%.	Dopamine	171-179	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	28-36
10516482-0	1999	Effects of chronic "Binge" cocaine administration on plasma ACTH and corticosterone levels in mice deficient in DARPP-32.	Cocaine	27-34	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-120
10516482-1	1999	The product of the DARPP-32 gene mediates intracellular signals initiated by the binding of dopamine to its receptors.	Dopamine	92-100	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-27
10516482-8	1999	The results indicate that DARPP-32 plays a role in mediating the stimulatory effects of cocaine on the HPA axis.	Cocaine	88-95	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	26-34
10217279-5	1999	Okadaic acid (1 microM), an inhibitor of PP-1 and PP-2A, had a smaller effect, increasing phospho-DARPP-32 by 5.1+/-1.3-fold.	Okadaic Acid	0-12	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	98-106
10217279-6	1999	The effect of okadaic acid on DARPP-32 phosphorylation was shown to be due to inhibition of PP-2A activity.	Okadaic Acid	14-26	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	30-38
10217279-7	1999	Incubation of slices in the presence of cyclosporin A plus either okadaic acid or calyculin A, another PP-1/PP-2A inhibitor, caused a synergistic increase in the level of phosphorylated DARPP-32.	Cyclosporine	40-53	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-194
10217279-7	1999	Incubation of slices in the presence of cyclosporin A plus either okadaic acid or calyculin A, another PP-1/PP-2A inhibitor, caused a synergistic increase in the level of phosphorylated DARPP-32.	Okadaic Acid	66-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-194
10217279-7	1999	Incubation of slices in the presence of cyclosporin A plus either okadaic acid or calyculin A, another PP-1/PP-2A inhibitor, caused a synergistic increase in the level of phosphorylated DARPP-32.	calyculin A	82-93	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	186-194
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-72	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	76-84
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-72	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	162-170
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-70	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	76-84
10217279-8	1999	The use of Ca2(+)-free/EGTA medium mimicked the effects of cyclosporin A on DARPP-32 phosphorylation, supporting the conclusion that the action of cyclosporin on DARPP-32 phosphorylation was attributable to blockade of the Ca2(+)-dependent activation of calcineurin.	Cyclosporine	59-70	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	162-170
9852567-5	1998	DA-induced phosphorylation of NR1 was blocked in mice bearing a targeted deletion of the gene for dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32), a phosphoprotein that is a potent and selective inhibitor of protein phosphatase-1, indicating that the effect of PKA is mediated, in part, by regulation of the DARPP-32/protein phosphatase-1 cascade.	Dopamine	0-2	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	156-164
10103106-3	1999	Repeated cocaine administration increased levels of DeltaFosB, a Fos family transcription factor, in the striatum of wild-type mice, and this increase was abolished in DARPP-32-mutant mice.	Cocaine	9-16	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	168-176
10103106-5	1999	These data show that DARPP-32 is involved in regulating substance P expression in the striatonigral pathway, and in biochemical and behavioural plasticity with chronic administration of cocaine.	Cocaine	186-193	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	21-29
9852567-5	1998	DA-induced phosphorylation of NR1 was blocked in mice bearing a targeted deletion of the gene for dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32), a phosphoprotein that is a potent and selective inhibitor of protein phosphatase-1, indicating that the effect of PKA is mediated, in part, by regulation of the DARPP-32/protein phosphatase-1 cascade.	Dopamine	0-2	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	328-336
9852567-5	1998	DA-induced phosphorylation of NR1 was blocked in mice bearing a targeted deletion of the gene for dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32), a phosphoprotein that is a potent and selective inhibitor of protein phosphatase-1, indicating that the effect of PKA is mediated, in part, by regulation of the DARPP-32/protein phosphatase-1 cascade.	Dopamine	98-106	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	328-336
9852567-5	1998	DA-induced phosphorylation of NR1 was blocked in mice bearing a targeted deletion of the gene for dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32), a phosphoprotein that is a potent and selective inhibitor of protein phosphatase-1, indicating that the effect of PKA is mediated, in part, by regulation of the DARPP-32/protein phosphatase-1 cascade.	Cyclic AMP	112-116	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	156-164
9852567-5	1998	DA-induced phosphorylation of NR1 was blocked in mice bearing a targeted deletion of the gene for dopamine- and cAMP-regulated phosphoprotein of Mr 32 kDa (DARPP-32), a phosphoprotein that is a potent and selective inhibitor of protein phosphatase-1, indicating that the effect of PKA is mediated, in part, by regulation of the DARPP-32/protein phosphatase-1 cascade.	Cyclic AMP	112-116	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	328-336
9694658-2	1998	Dopamine and adenosine 3",5"-monophosphate-regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor.	Dopamine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	86-94
9694658-2	1998	Dopamine and adenosine 3",5"-monophosphate-regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor.	adenosine 3"	13-25	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	86-94
9694658-2	1998	Dopamine and adenosine 3",5"-monophosphate-regulated phosphoprotein (32 kilodaltons) (DARPP-32), which is enriched in all neurons that receive a dopaminergic input, is converted in response to dopamine into a potent protein phosphatase inhibitor.	Dopamine	145-153	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	86-94
9694658-3	1998	Mice generated to contain a targeted disruption of the DARPP-32 gene showed profound deficits in their molecular, electrophysiological, and behavioral responses to dopamine, drugs of abuse, and antipsychotic medication.	Dopamine	164-172	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	55-63
9334390-0	1997	Bidirectional regulation of DARPP-32 phosphorylation by dopamine.	Dopamine	56-64	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	28-36
9334390-4	1997	The D1 receptor agonist SKF82526 increased DARPP-32 phosphorylation.	Fenoldopam	24-32	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	43-51
9334390-1	1997	Dopamine has been shown to stimulate phosphorylation of DARPP-32, a phosphoprotein highly enriched in medium-sized spiny neurons of the neostriatum.	Dopamine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	56-64
9334390-5	1997	In contrast, the D2 receptor agonist quinpirole decreased basal as well as D1 agonist-, forskolin-, and 8-bromo-cAMP-stimulated phosphorylation of DARPP-32.	Quinpirole	37-47	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
9334390-5	1997	In contrast, the D2 receptor agonist quinpirole decreased basal as well as D1 agonist-, forskolin-, and 8-bromo-cAMP-stimulated phosphorylation of DARPP-32.	Colforsin	88-97	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
9334390-5	1997	In contrast, the D2 receptor agonist quinpirole decreased basal as well as D1 agonist-, forskolin-, and 8-bromo-cAMP-stimulated phosphorylation of DARPP-32.	8-Bromo Cyclic Adenosine Monophosphate	104-116	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
9334390-6	1997	The ability of quinpirole to decrease D1-stimulated DARPP-32 phosphorylation was calcium-dependent and was blocked by the calcineurin inhibitor cyclosporin A, suggesting that the D2 effect involved an increase in intracellular calcium and activation of calcineurin.	Quinpirole	15-25	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	52-60
9334390-6	1997	The ability of quinpirole to decrease D1-stimulated DARPP-32 phosphorylation was calcium-dependent and was blocked by the calcineurin inhibitor cyclosporin A, suggesting that the D2 effect involved an increase in intracellular calcium and activation of calcineurin.	Calcium	81-88	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	52-60
9334390-6	1997	The ability of quinpirole to decrease D1-stimulated DARPP-32 phosphorylation was calcium-dependent and was blocked by the calcineurin inhibitor cyclosporin A, suggesting that the D2 effect involved an increase in intracellular calcium and activation of calcineurin.	Cyclosporine	144-157	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	52-60
9334390-6	1997	The ability of quinpirole to decrease D1-stimulated DARPP-32 phosphorylation was calcium-dependent and was blocked by the calcineurin inhibitor cyclosporin A, suggesting that the D2 effect involved an increase in intracellular calcium and activation of calcineurin.	Calcium	227-234	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	52-60
9334390-7	1997	In support of this interpretation, Ca2+-free/EGTA medium induced a greater than 60-fold increase in DARPP-32 phosphorylation and abolished the ability of quinpirole to dephosphorylate DARPP-32.	Egtazic Acid	45-49	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	100-108
9334390-7	1997	In support of this interpretation, Ca2+-free/EGTA medium induced a greater than 60-fold increase in DARPP-32 phosphorylation and abolished the ability of quinpirole to dephosphorylate DARPP-32.	Egtazic Acid	45-49	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	184-192
9334390-7	1997	In support of this interpretation, Ca2+-free/EGTA medium induced a greater than 60-fold increase in DARPP-32 phosphorylation and abolished the ability of quinpirole to dephosphorylate DARPP-32.	Quinpirole	154-164	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	184-192
9334390-8	1997	The antipsychotic drug raclopride, a selective D2 receptor antagonist, increased phosphorylation of DARPP-32 under basal conditions and in D2 agonist-treated slices.	Raclopride	23-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	100-108
9334390-9	1997	The results of this study demonstrate that dopamine exerts a bidirectional control on the state of phosphorylation of DARPP-32.	Dopamine	43-51	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	118-126
1280208-9	1992	GT1 cells also express the mRNA for the dopamine- and cAMP-regulated phospho-protein (mol wt, 32,000; DARPP-32) only seen in cells expressing DA D1-receptors.	Dopamine	40-48	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	102-110
8747155-1	1995	DARPP-32 (a dopamine and adenosine 3":5"-monophosphate (cAMP) regulated phosphoprotein of M(r) 32 kDa) and I-1 (phosphatase inhibitor-1) are related phosphoproteins that have distinct regional distributions in some specific neuronal structures.	Dopamine	12-20	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
8747155-1	1995	DARPP-32 (a dopamine and adenosine 3":5"-monophosphate (cAMP) regulated phosphoprotein of M(r) 32 kDa) and I-1 (phosphatase inhibitor-1) are related phosphoproteins that have distinct regional distributions in some specific neuronal structures.	Cyclic AMP	25-54	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
8747155-1	1995	DARPP-32 (a dopamine and adenosine 3":5"-monophosphate (cAMP) regulated phosphoprotein of M(r) 32 kDa) and I-1 (phosphatase inhibitor-1) are related phosphoproteins that have distinct regional distributions in some specific neuronal structures.	Cyclic AMP	56-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
7485543-1	1995	DARPP-32, a dopamine- and adenosine 3",5"-cyclic monophosphate (cAMP)-regulated inhibitor of protein phosphatase-1, is highly colocalized with neuronal and nonneuronal D1-type receptors.	Dopamine	12-20	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
7485543-1	1995	DARPP-32, a dopamine- and adenosine 3",5"-cyclic monophosphate (cAMP)-regulated inhibitor of protein phosphatase-1, is highly colocalized with neuronal and nonneuronal D1-type receptors.	Cyclic AMP	26-62	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
7485543-1	1995	DARPP-32, a dopamine- and adenosine 3",5"-cyclic monophosphate (cAMP)-regulated inhibitor of protein phosphatase-1, is highly colocalized with neuronal and nonneuronal D1-type receptors.	Cyclic AMP	64-68	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
7485543-3	1995	In the ascending limb of the loop of Henle, DARPP-32 is phosphorylated following stimulation by dopamine and other first messengers, and in this form inhibits the activity of the Na(+)-K(+)-adenosinetriphosphatase pump.	Dopamine	96-104	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	44-52
1280208-9	1992	GT1 cells also express the mRNA for the dopamine- and cAMP-regulated phospho-protein (mol wt, 32,000; DARPP-32) only seen in cells expressing DA D1-receptors.	Cyclic AMP	54-58	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	102-110
1533862-0	1992	Regional distribution of DARPP-32 (dopamine- and adenosine 3",5"-monophosphate-regulated phosphoprotein of Mr = 32,000) mRNA in mouse brain.	Dopamine	35-43	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	25-33
1533862-0	1992	Regional distribution of DARPP-32 (dopamine- and adenosine 3",5"-monophosphate-regulated phosphoprotein of Mr = 32,000) mRNA in mouse brain.	Cyclic AMP	49-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	25-33
1533862-1	1992	DARPP-32 (dopamine- and adenosine 3",5"-monophosphate-regulated phosphoprotein of Mr = 32,000) mRNA distribution was examined in adult mouse central nervous system by in situ hybridization.	Dopamine	10-18	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
34675407-5	2022	In mice, DARPP-32 ablation sensitizes gefitinib-resistant xenografts to EGFR TKIs, while DARPP-32 overexpression increases gefitinib-refractory LUAD progression in gefitinib-sensitive lung tumors.	Gefitinib	38-47	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	9-17
1721636-1	1991	The cellular localization of a dopamine- and adenosine-3",5"-monophosphate (cAMP)-regulated phosphoprotein of an apparent molecular weight of 32,000 (DARPP-32) was investigated in mouse, rat, rabbit, guinea pig, cat, monkey (Macaca fascicularis and Marmoset) and human adrenal gland by means of indirect immunofluorescence histochemistry.	Dopamine	31-39	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	150-158
1721636-1	1991	The cellular localization of a dopamine- and adenosine-3",5"-monophosphate (cAMP)-regulated phosphoprotein of an apparent molecular weight of 32,000 (DARPP-32) was investigated in mouse, rat, rabbit, guinea pig, cat, monkey (Macaca fascicularis and Marmoset) and human adrenal gland by means of indirect immunofluorescence histochemistry.	Cyclic AMP	45-74	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	150-158
1721636-1	1991	The cellular localization of a dopamine- and adenosine-3",5"-monophosphate (cAMP)-regulated phosphoprotein of an apparent molecular weight of 32,000 (DARPP-32) was investigated in mouse, rat, rabbit, guinea pig, cat, monkey (Macaca fascicularis and Marmoset) and human adrenal gland by means of indirect immunofluorescence histochemistry.	Cyclic AMP	76-80	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	150-158
34675407-5	2022	In mice, DARPP-32 ablation sensitizes gefitinib-resistant xenografts to EGFR TKIs, while DARPP-32 overexpression increases gefitinib-refractory LUAD progression in gefitinib-sensitive lung tumors.	Gefitinib	123-132	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	89-97
34675407-5	2022	In mice, DARPP-32 ablation sensitizes gefitinib-resistant xenografts to EGFR TKIs, while DARPP-32 overexpression increases gefitinib-refractory LUAD progression in gefitinib-sensitive lung tumors.	Gefitinib	164-173	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	89-97
34498115-6	2021	Expression of phosphorylated DARPP-32 (Thr34 and Thr75) was evaluated by immunohistochemistry as a marker of DA-related signal transduction.	Dopamine	109-111	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	29-37
34498115-0	2021	Energizing effects of bupropion on effortful behaviors in mice under positive and negative test conditions: modulation of DARPP-32 phosphorylation patterns.	Bupropion	22-31	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	122-130
33011857-7	2021	Increased DARPP32 Thr75/Thr34 phosphorylation ratio was observed, suggesting a suppression of phosphatase 1 inhibition, which may be involved in behavioral responses to MGO.	Pyruvaldehyde	169-172	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	10-17
33471948-0	2021	Impact of Caffeine on Ethanol Induced Stimulation and Sensitization: Changes in ERK and DARPP-32 Phosphorylation in Nucleus Accumbens.	Caffeine	10-18	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	88-96
32413367-5	2020	Molecular approaches, transgenic mouse models, pharmacological intervention and behavioral analysis were combined to uncover a regulatory pathway, which connects caffeine action with diurnal signaling via the key dopaminergic protein DARPP-32 and alters mood-related phenotypes in mice, which are often assessed in the context of antidepressant action.	Caffeine	162-170	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	234-242
32413367-7	2020	T75A-DARPP-32 mutant mice show reduced caffeine effects on CLOCK:BMAL1 and lack caffeine-induced effects on mood.	Caffeine	39-47	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	5-13
32413367-7	2020	T75A-DARPP-32 mutant mice show reduced caffeine effects on CLOCK:BMAL1 and lack caffeine-induced effects on mood.	Caffeine	80-88	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	5-13
31060804-10	2019	Cdk5 inhibition by roscovitine infusion prevented depressive-like behavior and reduced DARPP-32 phosphorylation at Thr75 in the nucleus accumbens.	Roscovitine	19-30	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	87-95
32445040-5	2022	SR positive cells in the striatum showed strong co-localization with dopamine- and cyclic AMP-regulated neuronal phosphoprotein (DARPP32) in wild type mice.	Cyclic AMP	83-93	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	129-136
31743694-8	2020	Under these conditions, enhanced cAMP response element binding protein (CREB) and dopamine and cAMP-regulated phosphoprotein, 32 kDa (DARPP32) phosphorylation, significantly higher brain-derived neurotrophic factor (BDNF) and DeltaFosB, but reduced tyrosine hydroxylase (TH) and dopamine D1 receptor (D1R) protein expression were found in the NAc, DS and VTA.	Tyrosine	249-257	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	134-141
31743694-9	2020	Striatal BDNF, phospho-DARPP32 and phospho-CREB levels were significantly associated with the levels of depressive-like behavior in these mice.	phosphorylleucylphenylalanine	15-22	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	23-30
31396053-13	2019	At the molecular level, modulation of D1 receptors altered IVM"s effects on dopamine and cyclic-AMP regulated phosphoprotein of 32 kDa (DARPP-32) phosphorylation.	Cyclic AMP	89-99	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	136-144
30505273-6	2018	Moreover, in a series of studies, including that presented here, experimental evidence suggests that in a mouse model of parkinsonism induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, c-Abl inhibition exerts an immediate effect improving motor impairments by normalizing altered activity in striatal postsynaptic signaling pathways mediated by Cdk5 (cyclin-dependent kinase 5) and DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein 32 kDa).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	145-189	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	388-396
30173406-6	2019	We found that STSS exposure elevated dopamine receptor D1 (DRD1) gene expression and decreased gene expression of its downstream modulator DARPP-32 (32-kDa dopamine- and cAMP-regulated phosphoprotein), which was paralleled by decreased H3 acetylation at its gene promoter region.	Cyclic AMP	170-174	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	139-147
30142394-9	2019	Gene expression analysis of transcripts involved in dopamine regulation revealed a main effect of ethanol exposure on dopamine- and cyclic adenosine monophosphate- regulated neuronal phosphoprotein (Darpp-32), a main effect of vitamin D diet on Dopamine 2 Receptors (D2R) and a main effect of Sex on Tyrosine Hydroxylase (TH) expression.	Dopamine	52-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	118-207
30142394-9	2019	Gene expression analysis of transcripts involved in dopamine regulation revealed a main effect of ethanol exposure on dopamine- and cyclic adenosine monophosphate- regulated neuronal phosphoprotein (Darpp-32), a main effect of vitamin D diet on Dopamine 2 Receptors (D2R) and a main effect of Sex on Tyrosine Hydroxylase (TH) expression.	Ethanol	98-105	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	118-207
30505273-6	2018	Moreover, in a series of studies, including that presented here, experimental evidence suggests that in a mouse model of parkinsonism induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, c-Abl inhibition exerts an immediate effect improving motor impairments by normalizing altered activity in striatal postsynaptic signaling pathways mediated by Cdk5 (cyclin-dependent kinase 5) and DARPP-32 (dopamine- and cyclic AMP-regulated phosphoprotein 32 kDa).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	145-189	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	398-454
29107639-4	2018	Activation of JNK in dSPN relies on cAMP-induced phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32kDa (DARPP-32), but does not require N-methyl-d-aspartate (NMDA) receptor transmission.	Cyclic AMP	36-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	72-124
30337665-2	2018	ERK1/2 activation by L-DOPA takes place through the crosstalk between D1R/AC/PKA/DARPP-32 pathway and NMDA/Ras pathway.	Levodopa	21-27	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	81-89
29462355-7	2018	Moreover, LOC14 preserved medium spiny neuronal marker dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32 000 (DARPP32) levels in the striatum of HD mice.	Cyclic AMP	69-79	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	133-140
29967033-4	2018	Our numerical model suggests that a positive feed-forward mechanism inhibiting nuclear phosphatase activity - possibly mediated by DARPP-32 (also known as PPP1R1B) - could be responsible for this non-linear pattern of nuclear PKA response, allowing for a better detection of the transient dopamine signals that are often associated with reward-mediated learning.	Dopamine	289-297	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	131-139
29967033-4	2018	Our numerical model suggests that a positive feed-forward mechanism inhibiting nuclear phosphatase activity - possibly mediated by DARPP-32 (also known as PPP1R1B) - could be responsible for this non-linear pattern of nuclear PKA response, allowing for a better detection of the transient dopamine signals that are often associated with reward-mediated learning.	Dopamine	289-297	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	155-162
29221855-10	2018	These findings indicate that TLR4 signaling is involved in emotional regulation through modulation of DARPP-32, which is a signaling hub that plays a critical role in the integration of numerous neurotransmitter systems, including dopamine and glutamate.	Dopamine	231-239	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	102-110
29221855-10	2018	These findings indicate that TLR4 signaling is involved in emotional regulation through modulation of DARPP-32, which is a signaling hub that plays a critical role in the integration of numerous neurotransmitter systems, including dopamine and glutamate.	Glutamic Acid	244-253	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	102-110
29107639-4	2018	Activation of JNK in dSPN relies on cAMP-induced phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32kDa (DARPP-32), but does not require N-methyl-d-aspartate (NMDA) receptor transmission.	Cyclic AMP	36-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	126-134
29209158-8	2017	The results from our histological examinations revealed no signs of tumors and evidence that many iPS-NSCs survived and differentiated into region-specific neurons (medium spiny neurons) in both WT and HD mice, as confirmed by co-labeling of Hoechst-labeled transplanted cells with NeuN and DARPP-32.	hoechst	242-249	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	291-299
29209158-9	2017	Also, counts of Hoechst-labeled cells revealed that a higher proportion were co-labeled with DARPP-32 and NeuN in HD-, compared to WT- mice, suggesting a dissimilar differentiation pattern in HD mice.	hoechst	16-23	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	93-101
27837920-8	2017	Integrative analyses further found differentially expressed genes to cluster in functional networks and canonical pathways associated with mental illness and molecular signaling processes (e.g., glutamatergic, monoaminergic, calcium, cyclic adenosine monophosphate [cAMP], dopamine- and cAMP-regulated neuronal phosphoprotein 32 kDa [DARPP-32], and cAMP responsive element binding protein signaling [CREB]).	Dopamine	273-281	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	334-342
28359739-8	2017	DNP at a low dose (1mg/kg/day) significantly improved motor function and preserved medium spiny neuronal marker DARPP32 and postsynaptic protein PSD95 in the striatum of HD mice.	2,4-Dinitrophenol	0-3	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-119
28580946-8	2017	We found that mice with deletion of dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32) exclusively in D2R-expressing cells exhibited preferential D2R changes in the nucleus accumbens (NAc), a striatal region that critically regulates sucrose reinforcement.	Sucrose	247-254	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	36-88
28580946-8	2017	We found that mice with deletion of dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32) exclusively in D2R-expressing cells exhibited preferential D2R changes in the nucleus accumbens (NAc), a striatal region that critically regulates sucrose reinforcement.	Sucrose	247-254	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	90-98
27837920-8	2017	Integrative analyses further found differentially expressed genes to cluster in functional networks and canonical pathways associated with mental illness and molecular signaling processes (e.g., glutamatergic, monoaminergic, calcium, cyclic adenosine monophosphate [cAMP], dopamine- and cAMP-regulated neuronal phosphoprotein 32 kDa [DARPP-32], and cAMP responsive element binding protein signaling [CREB]).	Cyclic AMP	287-291	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	334-342
27837920-8	2017	Integrative analyses further found differentially expressed genes to cluster in functional networks and canonical pathways associated with mental illness and molecular signaling processes (e.g., glutamatergic, monoaminergic, calcium, cyclic adenosine monophosphate [cAMP], dopamine- and cAMP-regulated neuronal phosphoprotein 32 kDa [DARPP-32], and cAMP responsive element binding protein signaling [CREB]).	Cyclic AMP	287-291	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	334-342
28167675-5	2017	In support of this hypothesis, conditional knock-out of ARPP-16 in CaMKIIalpha::cre/floxed ARPP-16/19 mice results in dephosphorylation of a subset of PP2A substrates including phospho-Thr75-DARPP-32, phospho-T308-Akt, and phospho-T202/Y204-ERK.	arpp	56-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	191-199
28492670-5	2017	In terms of proteomic changes, krill oil resulted in upregulation of the Celsr3 and Ppp1r1b gene expression, which contribute to brain development, learning and memory behavior processes.	krill oil	31-40	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	84-91
28492670-6	2017	In particular, the Ppp1r1b gene is associated with the inhibition of dopamine releases, which decreases the motivation for learning.	Dopamine	69-77	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	19-26
27480796-6	2016	Quinpirole increased DARPP-32 phosphorylation at Thr75 and haloperidol at Ser97, two modifications that can have similar consequences on adducin phosphorylation through distinct mechanisms.	Quinpirole	0-10	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	21-29
27044354-4	2016	MCH has been shown to potentiate responses to dopamine and to increase phosphorylation of DARPP-32, an intracellular marker of DA receptor activation, in the NAcSh.	nacsh	158-163	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	90-98
26657176-2	2016	The dopamine and adenosine 3",5"-cyclic monophosphate-regulated phosphoprotein of 32kDa (DARPP-32) is enriched in the medium spiny neurons (MSNs) of the striatum and has been implicated in the actions of PCP.	Dopamine	4-12	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	89-97
26657176-2	2016	The dopamine and adenosine 3",5"-cyclic monophosphate-regulated phosphoprotein of 32kDa (DARPP-32) is enriched in the medium spiny neurons (MSNs) of the striatum and has been implicated in the actions of PCP.	adenosine 3"	17-29	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	89-97
26657176-2	2016	The dopamine and adenosine 3",5"-cyclic monophosphate-regulated phosphoprotein of 32kDa (DARPP-32) is enriched in the medium spiny neurons (MSNs) of the striatum and has been implicated in the actions of PCP.	pcp	204-207	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	89-97
26657176-8	2016	RESULTS: Loss of DARPP-32 in direct MSNs prevents PCP-induced phosphorylation and abolishes the motor stimulation effects of PCP.	pcp	50-53	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	17-25
26657176-8	2016	RESULTS: Loss of DARPP-32 in direct MSNs prevents PCP-induced phosphorylation and abolishes the motor stimulation effects of PCP.	pcp	125-128	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	17-25
26657176-11	2016	CONCLUSIONS: The increase in DARPP-32 phosphorylation induced by PCP occurs selectively in the MSNs of the direct pathway, which are also specifically involved in the motor stimulant effects of this drug.	pcp	65-68	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	29-37
27044354-9	2016	The increase in DARPP-32 phosphorylation seen in wildtype (WT) mice after acute alcohol administration in the NAcSh was markedly reduced in MCH1-R knock-out (KO) mice.	Alcohols	80-87	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
27044354-9	2016	The increase in DARPP-32 phosphorylation seen in wildtype (WT) mice after acute alcohol administration in the NAcSh was markedly reduced in MCH1-R knock-out (KO) mice.	nacsh	110-115	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
26094900-8	2015	Coherent with protective effects, pridopidine-mediated beneficial effects in R6/2 mice were associated with an increased expression of pro-survival and neurostimulatory molecules, such as brain derived neurotrophic factor and DARPP32, and with a reduction in the size of mHtt aggregates in striatal tissues.	pridopidine	34-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	226-233
26639316-5	2015	Phospho-Thr75-DARPP-32 facilitates beta-adducin Ser713 phosphorylation through inhibition of a cAMP-dependent protein kinase/phosphatase-2A cascade.	Cyclic AMP	95-99	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	14-22
26146906-12	2015	Conversely, methamphetamine-induced locomotor activity was attenuated in DKO mice, accompanied by reductions in dopamine and HVA content and impaired DARPP-32 activation.	Methamphetamine	12-27	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	150-158
25288320-6	2015	Most of the changes, such as the modification of the dopamine-DARPP-32 signalling pathway, were common in both areas and estimated to have neuronal origin.	Dopamine	53-61	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	62-70
26465004-6	2015	The PKA-dependent effects in D2 MSNs were prevented in brain slices and in vivo by mutation of the PKA-regulated phosphorylation site of 32 kDa dopamine- and cAMP-regulated phosphoprotein (DARPP-32), which is required for protein phosphatase-1 inhibition.	Dopamine	144-152	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	189-197
26465004-6	2015	The PKA-dependent effects in D2 MSNs were prevented in brain slices and in vivo by mutation of the PKA-regulated phosphorylation site of 32 kDa dopamine- and cAMP-regulated phosphoprotein (DARPP-32), which is required for protein phosphatase-1 inhibition.	Cyclic AMP	158-162	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	189-197
26465004-7	2015	These data highlight differences in the integration of the cAMP signal in D1 and D2 MSNs, resulting from stronger inhibition of protein phosphatase-1 by DARPP-32 in D2 MSNs than in D1 MSNs.	Cyclic AMP	59-63	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	153-161
26099530-0	2015	Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Delta9-Tetrahydrocannabinol-Mediated Induction of DeltaFosB in the Mouse Forebrain.	Dronabinol	95-122	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	38-91
26099530-5	2015	Dopamine signaling in the striatum involves phosphorylation-specific effects of the dopamine- and cAMP-regulated phosphoprotein Mr 32 kDa (DARPP-32), which regulates protein kinase A signaling.	Dopamine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	84-137
26099530-5	2015	Dopamine signaling in the striatum involves phosphorylation-specific effects of the dopamine- and cAMP-regulated phosphoprotein Mr 32 kDa (DARPP-32), which regulates protein kinase A signaling.	Dopamine	0-8	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	139-147
26099530-7	2015	THC was then acutely or repeatedly administered to wild-type (WT) and DARPP-32 knockout (KO) mice, and in vivo responses were measured.	Dronabinol	0-3	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	70-78
26099530-8	2015	DARPP-32 KO mice exhibited enhanced acute THC-mediated hypolocomotion and developed greater tolerance to this response relative to the WT mice.	Dronabinol	42-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	0-8
26099530-9	2015	Agonist-stimulated guanosine 5"-O-(3-[(35)S]thio)triphosphate ([(35)S]GTPgammaS) binding showed that cannabinoid-stimulated G-protein activity did not differ between DARPP-32 KO and WT mice treated with vehicle or repeated THC.	Cannabinoids	101-112	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	166-174
26099530-10	2015	These results indicate that D1Rs play a major role in THC-mediated DeltaFosB induction in the forebrain, whereas the role of DARPP-32 in THC-mediated DeltaFosB induction and modulation of motor activity appears to be more complex.	Dronabinol	137-140	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	125-133
25288320-9	2015	In conclusion, frustration behaviour-induced changes in frontal cortex and ventral striatum mainly related to dopamine-DARPP-32 signalling that could play an important role in the loss of behavioural control during the addictive processes.	Dopamine	110-118	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	119-127
25027318-5	2014	These Ube3a-maternal deficient HD mice also showed drastic reduction of DARPP-32, a dopamine-regulated phoshphoprotein in their striatum.	Dopamine	84-92	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	72-80
24919054-0	2014	Individual differences in ethanol locomotor sensitization are associated with dopamine D1 receptor intra-cellular signaling of DARPP-32 in the nucleus accumbens.	Ethanol	26-33	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	127-135
24907589-10	2014	Gene expression was altered in pathways of inflammation and G-protein coupled receptors in prefrontal cortex and amygdala; in the latter, expression of genes important in dopamine function were de-regulated including down-regulated Drd2, Adora2a and Darpp-32.	Dopamine	171-179	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	250-258
24726488-9	2014	The TH-positive innervation overlapped with the organization of dopamine and cyclic AMP-regulated phosphoprotein-relative molecular mass 32,000 (DARPP-32)-positive neurons, that was disorganized in LGE lacking GDNF production.	Cyclic AMP	77-87	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	145-153
24919054-3	2014	Here we investigated if the functional hyperresponsiveness of D1 receptors observed in ethanol sensitized mice leads to an increased activation of DARPP-32, a central regulatory protein in medium spiny neurons, in the nucleus accumbens - a brain region known to play a role in drug reinforcement.	Ethanol	87-94	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
24555476-4	2014	Roscovitine is a potent Cdk5 inhibitor; it has been previously shown that acute application of Roscovitine increases striatal transmission via Cdk5/DARPP-32.	Roscovitine	0-11	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	148-156
24440754-0	2014	Haloperidol-induced Nur77 expression in striatopallidal neurons is under the control of protein phosphatase 1 regulation by DARPP-32.	Haloperidol	0-11	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	124-132
24440754-9	2014	In contrast, in DARPP-32 knock-in mutant mice bearing a T34A point mutation of the site responsible for cAMP-dependent phosphatase 1 inhibition, Nur77 up-regulation by haloperidol was prevented.	Cyclic AMP	104-108	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
24440754-9	2014	In contrast, in DARPP-32 knock-in mutant mice bearing a T34A point mutation of the site responsible for cAMP-dependent phosphatase 1 inhibition, Nur77 up-regulation by haloperidol was prevented.	Haloperidol	168-179	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
24555476-4	2014	Roscovitine is a potent Cdk5 inhibitor; it has been previously shown that acute application of Roscovitine increases striatal transmission via Cdk5/DARPP-32.	Roscovitine	95-106	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	148-156
24600352-1	2014	Abnormal motor behaviors in Parkinson"s disease (PD) result from striatal dysfunction due to an imbalance between dopamine and glutamate transmissions that are integrated by dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32).	Dopamine	114-122	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	174-227
24316474-8	2014	rescued reduced levels of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation and phosphorylation at Thr-34 of dopamine- and cAMP-regulated phosphoprotein-32 (DARPP-32) in striatum and hippocampal CA1 to levels seen in sham-operated mice.	Threonine	124-127	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	134-180
24316474-8	2014	rescued reduced levels of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) autophosphorylation and phosphorylation at Thr-34 of dopamine- and cAMP-regulated phosphoprotein-32 (DARPP-32) in striatum and hippocampal CA1 to levels seen in sham-operated mice.	Threonine	124-127	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	182-190
23290496-9	2013	In support of this hypothesis, D1R levels were upregulated in the knockout mice, as well as phosphorylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [cAMP]-regulated phospho-protein of 32 kDa), most of the behavioral phenotypes were abolished by the D1R antagonist, SCH23390, and the D2-MSN knockout mice displayed no obvious behavioral phenotype.	Dopamine	121-129	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	111-119
24312250-4	2013	The inactivation of A2ARs in GABAergic neurons reduced striatal DARPP-32 phosphorylation at Thr-34 and increased its phosphorylation at Thr-75.	Threonine	92-95	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	64-72
24312250-5	2013	Conversely, the additional deletion of corticostriatal glutamatergic A2ARs produced opposite effects on DARPP-32 phosphorylation at Thr-34 and Thr-75.	Threonine	132-135	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	104-112
24312250-6	2013	This distinct modulation of DARPP-32 phosphorylation was associated with opposite responses to cocaine-induced striatal c-Fos expression and psychomotor activity in striatum-A2AR KO (enhanced) and forebrain-A2AR KO mice (reduced).	Cocaine	95-102	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	28-36
24312250-7	2013	Thus, A2ARs in glutamatergic corticostriatal terminals and in GABAergic striatal neurons modulate the action of psychostimulants and DARPP-32 phosphorylation in opposite ways.	a2ars	6-11	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	133-141
23786641-5	2013	Biochemical studies in the ventral striatum show that phosphorylation of DARPP-32(Thr) (-34) and GluR1(Ser) (-845) is diminished in MC4R-null mice after chronic cocaine administration but rescued in MC4R/D1R mice.	Threonine	82-85	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	73-81
23819855-9	2013	Moreover, these findings implicate the D1R/cAMP/DARPP-32 signaling pathway in those neurodevelopmental disorders that are associated with fine motor skill deficits.	Cyclic AMP	43-47	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	48-56
23290496-9	2013	In support of this hypothesis, D1R levels were upregulated in the knockout mice, as well as phosphorylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [cAMP]-regulated phospho-protein of 32 kDa), most of the behavioral phenotypes were abolished by the D1R antagonist, SCH23390, and the D2-MSN knockout mice displayed no obvious behavioral phenotype.	SCH 23390	283-291	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	111-119
24600352-1	2014	Abnormal motor behaviors in Parkinson"s disease (PD) result from striatal dysfunction due to an imbalance between dopamine and glutamate transmissions that are integrated by dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32).	Dopamine	114-122	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	229-237
24600352-1	2014	Abnormal motor behaviors in Parkinson"s disease (PD) result from striatal dysfunction due to an imbalance between dopamine and glutamate transmissions that are integrated by dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32).	Glutamic Acid	127-136	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	174-227
24600352-1	2014	Abnormal motor behaviors in Parkinson"s disease (PD) result from striatal dysfunction due to an imbalance between dopamine and glutamate transmissions that are integrated by dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32).	Glutamic Acid	127-136	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	229-237
24600352-3	2014	Here, we report that in the mouse striatum, a novel c-Abl inhibitor, nilotinib (AMN107), inhibits phosphorylation of both Cdk5 at Tyr15 and DARPP-32 at Thr75, which is negatively regulated by dopamine receptor activation through a D2 receptor-mediated mechanism.	nilotinib	69-78	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	140-148
24600352-3	2014	Here, we report that in the mouse striatum, a novel c-Abl inhibitor, nilotinib (AMN107), inhibits phosphorylation of both Cdk5 at Tyr15 and DARPP-32 at Thr75, which is negatively regulated by dopamine receptor activation through a D2 receptor-mediated mechanism.	nilotinib	80-86	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	140-148
23906769-0	2013	Methylphenidate restores novel object recognition in DARPP-32 knockout mice.	Methylphenidate	0-15	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	53-61
23906769-10	2013	In contrast, pretreatment with methylphenidate restored the behavior of DARPP-32 knockout mice to that observed in wild-type mice given saline.	Methylphenidate	31-46	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	72-80
23906769-10	2013	In contrast, pretreatment with methylphenidate restored the behavior of DARPP-32 knockout mice to that observed in wild-type mice given saline.	Sodium Chloride	136-142	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	72-80
23906769-12	2013	These results also indicate that the behavioral deficits in DARPP-32 knockout mice may be restored by the administration of methylphenidate.	Methylphenidate	124-139	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	60-68
23290496-9	2013	In support of this hypothesis, D1R levels were upregulated in the knockout mice, as well as phosphorylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [cAMP]-regulated phospho-protein of 32 kDa), most of the behavioral phenotypes were abolished by the D1R antagonist, SCH23390, and the D2-MSN knockout mice displayed no obvious behavioral phenotype.	Cyclic AMP	135-165	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	111-119
23290496-9	2013	In support of this hypothesis, D1R levels were upregulated in the knockout mice, as well as phosphorylation of DARPP-32 (dopamine- and cyclic adenosine monophosphate [cAMP]-regulated phospho-protein of 32 kDa), most of the behavioral phenotypes were abolished by the D1R antagonist, SCH23390, and the D2-MSN knockout mice displayed no obvious behavioral phenotype.	Cyclic AMP	167-171	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	111-119
23303063-4	2013	In the adora2A-rM3Ds mouse, activation of rM3Ds by clozapine-N-oxide (CNO) induces DARPP-32 phosphorylation, consistent with the known consequence of activation of endogenous striatal Galphas-coupled GPCRs.	clozapine N-oxide	70-73	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	83-91
23551948-5	2013	We identified three molecular determinants underlying these differences: different activities of phosphodiesterases, particularly those of type 4, which strongly damp the cAMP signal in the cortex but not in the striatum; stronger adenylyl cyclase activity in the striatum, generating responses with a faster onset than in the cortex; and DARPP-32, a phosphatase inhibitor which prolongs PKA action in the striatum.	Cyclic AMP	171-175	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	339-347
23446639-7	2013	Moreover, 4"-DMA-7,8-DHF preserved DARPP32 levels in the striatum and rescued mutant huntingtin-induced impairment of neurogenesis in the N171-82Q HD mice.	4"-dma-7,8-dhf	10-24	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	35-42
23420105-5	2013	Moreover, in the 1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine (MPTP) mouse model, dopamine deficiency caused increased phosphorylation of both Tyr15-Cdk5 and Thr75-DARPP-32 in the striatum, which could be attenuated by administration of L-3,4-dihydroxyphenylalanine and imatinib (STI-571), a selective c-Abl inhibitor.	1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine	17-61	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	164-172
22507666-6	2013	The ability of DHPG to increase PKA-dependent phosphorylation of GluA1 depends on concomitant activation of the dopamine- and cAMP-regulated phosphoprotein of 32kDa (DARPP-32).	3,5-dihydroxyphenylglycine	15-19	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-164
22507666-6	2013	The ability of DHPG to increase PKA-dependent phosphorylation of GluA1 depends on concomitant activation of the dopamine- and cAMP-regulated phosphoprotein of 32kDa (DARPP-32).	3,5-dihydroxyphenylglycine	15-19	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	166-174
22507666-7	2013	Thus, inactivation of the PKA phosphorylation site of DARPP-32 abolishes the effect of DHPG.	3,5-dihydroxyphenylglycine	87-91	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	54-62
22507666-8	2013	Moreover, cell-specific knock out of DARPP-32 in striatopallidal, but not in striatonigral, MSNs prevents the increase in Ser845 phosphorylation induced by DHPG.	3,5-dihydroxyphenylglycine	156-160	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	37-45
22507666-9	2013	These results indicate that activation of mGlu5Rs promotes PKA/DARPP-32-dependent phosphorylation of downstream target proteins in striatopallidal MSNs and that this effect is exerted via potentiation of tonic A2AR transmission.	mglu5rs	42-49	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	63-71
23420105-2	2013	Glutamate inputs activate cyclin-dependent kinase 5 (Cdk5), which inhibits postsynaptic dopamine signaling by phosphorylating DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, 32 kDa) at Thr75 in the striatum.	Glutamic Acid	0-9	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	126-134
23420105-2	2013	Glutamate inputs activate cyclin-dependent kinase 5 (Cdk5), which inhibits postsynaptic dopamine signaling by phosphorylating DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, 32 kDa) at Thr75 in the striatum.	Dopamine	88-96	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	126-134
23303063-4	2013	In the adora2A-rM3Ds mouse, activation of rM3Ds by clozapine-N-oxide (CNO) induces DARPP-32 phosphorylation, consistent with the known consequence of activation of endogenous striatal Galphas-coupled GPCRs.	clozapine N-oxide	51-68	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	83-91
23420105-5	2013	Moreover, in the 1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine (MPTP) mouse model, dopamine deficiency caused increased phosphorylation of both Tyr15-Cdk5 and Thr75-DARPP-32 in the striatum, which could be attenuated by administration of L-3,4-dihydroxyphenylalanine and imatinib (STI-571), a selective c-Abl inhibitor.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	63-67	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	164-172
23420105-2	2013	Glutamate inputs activate cyclin-dependent kinase 5 (Cdk5), which inhibits postsynaptic dopamine signaling by phosphorylating DARPP-32 (dopamine- and cAMP-regulated phosphoprotein, 32 kDa) at Thr75 in the striatum.	Cyclic AMP	150-154	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	126-134
23420105-5	2013	Moreover, in the 1-methyl-4-phenyl-1,2,4,6-tetrahydropyridine (MPTP) mouse model, dopamine deficiency caused increased phosphorylation of both Tyr15-Cdk5 and Thr75-DARPP-32 in the striatum, which could be attenuated by administration of L-3,4-dihydroxyphenylalanine and imatinib (STI-571), a selective c-Abl inhibitor.	Dopamine	82-90	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	164-172
22971543-3	2012	In this study, we investigated the function of muscarinic receptors in the striatum by monitoring DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa) phosphorylation at Thr34 (the PKA-site) using mouse striatal slices.	Dopamine	108-116	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	98-106
23555817-9	2013	Pathway analysis detected a prefrontal cortex-based dopamine-related (PPP1R1B, DRD1, DRD2, FOSB, PDNY) network that was highly over-represented in the Chronic Intermittent group, with several genes from the network being also regulated in the Chronic and lipopolysaccharide (but not Drinking in the Dark) groups.	Dopamine	52-60	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	70-77
22971543-3	2012	In this study, we investigated the function of muscarinic receptors in the striatum by monitoring DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of M(r) 32 kDa) phosphorylation at Thr34 (the PKA-site) using mouse striatal slices.	Cyclic AMP	122-126	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	98-106
22971543-4	2012	Treatment of slices with a non-selective muscarinic receptor agonist, oxotremorine (10 muM), rapidly and transiently increased DARPP-32 phosphorylation.	Oxotremorine	70-82	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	127-135
22971543-5	2012	The increase in DARPP-32 phosphorylation was completely abolished either by a dopamine D(1) receptor antagonist (SCH23390), tetrodotoxin, genetic deletion of M5 receptors, muscarinic toxins for M1 and M4 receptors, or 6-hydroxydopamine lesioning of dopaminergic neurons, whereas it was enhanced by nicotine.	Tetrodotoxin	124-136	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
22971543-5	2012	The increase in DARPP-32 phosphorylation was completely abolished either by a dopamine D(1) receptor antagonist (SCH23390), tetrodotoxin, genetic deletion of M5 receptors, muscarinic toxins for M1 and M4 receptors, or 6-hydroxydopamine lesioning of dopaminergic neurons, whereas it was enhanced by nicotine.	Oxidopamine	218-235	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
22971543-5	2012	The increase in DARPP-32 phosphorylation was completely abolished either by a dopamine D(1) receptor antagonist (SCH23390), tetrodotoxin, genetic deletion of M5 receptors, muscarinic toxins for M1 and M4 receptors, or 6-hydroxydopamine lesioning of dopaminergic neurons, whereas it was enhanced by nicotine.	Nicotine	298-306	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	16-24
22971543-6	2012	Analysis in D(1)-DARPP-32-Flag/D(2)-DARPP-32-Myc transgenic mice revealed that oxotremorine increases DARPP-32 phosphorylation selectively in D(1)-type/striatonigral, but not in D(2)-type/striatopallidal, neurons.	Oxotremorine	79-91	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	17-25
22971543-6	2012	Analysis in D(1)-DARPP-32-Flag/D(2)-DARPP-32-Myc transgenic mice revealed that oxotremorine increases DARPP-32 phosphorylation selectively in D(1)-type/striatonigral, but not in D(2)-type/striatopallidal, neurons.	Oxotremorine	79-91	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	36-44
22971543-6	2012	Analysis in D(1)-DARPP-32-Flag/D(2)-DARPP-32-Myc transgenic mice revealed that oxotremorine increases DARPP-32 phosphorylation selectively in D(1)-type/striatonigral, but not in D(2)-type/striatopallidal, neurons.	Oxotremorine	79-91	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	36-44
22971543-7	2012	When D(1) and D(2) receptors were blocked by selective antagonists to exclude the effects of released dopamine, oxotremorine increased DARPP-32 Thr34 phosphorylation only in D(2)-type/striatopallidal neurons.	Oxotremorine	112-124	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	135-143
23131156-8	2012	Most importantly, GFP-positive cells further differentiate to dopaminergic (TH-positive) and medium size spiny (DARPP-32- positive) neuronal phenotypes.	positive	22-30	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	112-120
22753408-3	2012	Using mice in which DARPP-32 is selectively deleted in D1R-expressing MSNs, we demonstrate that this protein is required for l-DOPA-induced activation of the extracellular signal-regulated protein kinases 1 and 2 and the mammalian target of rapamycin complex 1 (mTORC1) pathways, which are implicated in dyskinesia.	Levodopa	125-131	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	20-28
21720791-6	2012	Monolayer method-derived GABAergic neurons expressed the MSN marker dopamine- and cyclic AMP-regulated phosphoprotein (DARPP32).	Cyclic AMP	82-92	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	119-126
22564758-2	2012	This study investigates the effects of naloxonazine, a specific mu-opioid receptor antagonist, on the locomotor behavioral response and phosphorylation pattern of dopamine and cAMP-regulated phosphoprotein of Mr32 (DARPP-32) in striatal dopaminergic transmissions induced by acute administration of METH to mice.	naloxonazine	39-51	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	163-213
22564758-2	2012	This study investigates the effects of naloxonazine, a specific mu-opioid receptor antagonist, on the locomotor behavioral response and phosphorylation pattern of dopamine and cAMP-regulated phosphoprotein of Mr32 (DARPP-32) in striatal dopaminergic transmissions induced by acute administration of METH to mice.	naloxonazine	39-51	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	215-223
22564758-2	2012	This study investigates the effects of naloxonazine, a specific mu-opioid receptor antagonist, on the locomotor behavioral response and phosphorylation pattern of dopamine and cAMP-regulated phosphoprotein of Mr32 (DARPP-32) in striatal dopaminergic transmissions induced by acute administration of METH to mice.	Methamphetamine	299-303	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	163-213
22564758-2	2012	This study investigates the effects of naloxonazine, a specific mu-opioid receptor antagonist, on the locomotor behavioral response and phosphorylation pattern of dopamine and cAMP-regulated phosphoprotein of Mr32 (DARPP-32) in striatal dopaminergic transmissions induced by acute administration of METH to mice.	Methamphetamine	299-303	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	215-223
22564758-7	2012	Results show that pretreatment with naloxonazine significantly attenuated the acute METH-induced increase in locomotor activity and phosphor-Thr75 DARPP-32 levels.	naloxonazine	36-48	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155
22564758-7	2012	Results show that pretreatment with naloxonazine significantly attenuated the acute METH-induced increase in locomotor activity and phosphor-Thr75 DARPP-32 levels.	Methamphetamine	84-88	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	147-155